Section |
Name |
Details |
14.04 |
23-valent pneumococcal polysaccharide vaccine |
|
13.08.01 |
5-Aminolaevulinic acid Ameluz® |
Dermatology only
|
15.03 |
5-aminolevulinic acid Gliolan® |
For visualisation of malignant tissue during surgery for malignant glioma |
05.03.01 |
Abacavir |
|
05.03.01 |
Abacavir/lamivudine Kivexa® |
|
05.03.01 |
Abacavir/lamivudine/zidovudine Tizivir® |
|
10.01.03 |
Abatacept Orencia® |
|
02.09 |
Abciximab |
|
08.01.05 |
Abemaciclib Verzenios® |
|
08.03.04.02 |
Abiraterone |
|
04.10.01 |
Acamprosate Campral EC® |
|
03.12 |
Acapella Choice® |
Oscillating Positive Expiratory Pressure (OPEP) device.
Third-line, for patients unsuitable for PARI O-PEP or Aerobika device.
For initiation by specialist physiotherapist or respiratory clinician only. For airways clearance in selected patients with chronic sputum-producing lung disease, e.g. cystic fibrosis, bronchiectasis, COPD.
All follow up and monitoring of patients, and routine replacement of devices to be carried out in secondary care.
Primary care prescribing on FP10 only when required for urgent supply of additional/replacement device (Drug Tariff listed approved appliance).
|
06.01.02.03 |
Acarbose |
|
11.06 |
Acetazolamide |
|
11.06 |
Acetazolamide |
|
12.01.01 |
Acetic acid 2% Earcalm ® |
A first-line option for acute otitis externa (refer to South Central Antimicrobial Network Guidelines for Antibiotic Prescribing in the Community 2018)
Self Care Medicine
|
13.11.01 |
Acetone BP |
|
11.08.02 |
Acetylcholine chloride 1% Miochol-E® |
|
03.07 |
Acetylcysteine |
Off-label use of injection.
Specialist initiation only for idiopathic pulmonary fibrosis.
|
03.07 |
Acetylcysteine NACSYS® |
Specialist initation only for idiopathic pulmonary fibrosis
|
18 |
Acetylcysteine Parvolex |
|
11.08.01 |
Acetylcysteine (with hypromellose) Ilube® |
|
05.03.02.01 |
Aciclovir |
|
05.03.02.01 |
Aciclovir |
|
11.03.03 |
Aciclovir 3% |
Zovirax® brand discontinued in Dec 2018. Generic 3% now available.
|
13.10.03 |
Aciclovir 5% |
Can be purchased OTC for cold sores.
|
13.05.02 |
Acitretin |
Specialist prescribing only
|
03.01.02 |
Aclidinium Eklira Genuair® |
Prescribing by brand name recommended
Licensed for COPD only, not for asthma |
03.01.04 |
Aclidinium and formoterol Duaklir Genuair® |
Prescribing by brand name recommended
|
18 |
Activated charcoal |
|
01.05.03 |
Adalimumab/ adalimumab biosimilar Humira®, Imraldi®, Amgevita®) (Gastroenterology |
Specify brand.
Severe Crohn’s disease if failed on infliximab
Imraldi and Amgevita are black triangle.
|
10.01.03 |
Adalimumab/ adalimumab biosimilar Humira®, Imraldi®, Amgevita® ) (Rheumatology |
Specify brand
Imraldi and Amgevita are black triangle
|
11.04 |
Adalimumab/ adalimumab biosimilar Humira®, Imraldi®, Amgevita®) (Ophthalmology |
Specify brand.
NHS England Specialised Commissioning- For uveitis
Imraldi and Amgevita are black triangle
|
13.05.03 |
Adalimumab/ adalimumab biosimilar Humira®, Imraldi®, Amgevita®) (dermatology |
Specify brand.
Specialist centres only for moderate to severe hidradenitis suppurativa - commissioned by NHS England in accordance with NICE TA392.
Amgevita and Imraldi are black triangle
|
13.06.01 |
Adapalene 0.1% |
|
13.06.01 |
Adapalene and benzoyl peroxide Epiduo® |
Mild to moderate papulopustular acne: Epiduo 0.1% gel (adapalene 0.1%/benzoyl peroxide 2.5%)
Moderate to severe papulopustular acne: Epiduo 0.3% gel (adapalene 0.3%/benzoyl peroxide 2.5%)
|
05.03.03.01 |
Adefovir Dipivoxil |
|
02.03.02 |
Adenosine Adenocor® |
|
03.04.03 |
Adrenaline / Epinephrine |
|
03.04.03 |
Adrenaline / epinephrine |
Prescribe by brand name (Emerade/Epipen/Jext)
for IM self administration |
02.07.03 |
Adrenaline 1 in 10,000 |
|
03.12 |
Aerobika® |
Oscillating Positive Expiratory Pressure (OPEP) device.
Second-line, for patients unsuitable for PARI O-PEP device.
For initiation by specialist physiotherapist or respiratory clinician only. For airways clearance in selected patients with chronic sputum-producing lung disease, e.g. cystic fibrosis, bronchiectasis, COPD.
All follow up and monitoring of patients, and routine replacement of devices to be carried out in secondary care.
Primary care prescribing on FP10 only when required for urgent supply of additional/replacement device (Drug Tariff listed approved appliance).
|
03.01.05 |
AeroChamber Plus ® |
|
08.01.05 |
Afatinib |
|
11.08.02 |
Aflibercept |
|
04.03.04 |
Agomelatine |
For use within Southern Health. Initiated or recommended by a psychiatrist.
A third line option where adverse effects of alternative antidepressants make them unacceptable to patients (sexual dysfunction and sleep disturbance) |
02.03.02 |
Ajmaline |
unlicensed
Cardiology use only. For provocative challenge in Brugada Syndrome
|
05.05 |
Albendazole |
unlicensed
|
13.11.01 |
Alcohol 70% |
From NHS Logistics. |
08.01.05 |
Alectinib Alecensa® |
|
08.02.04 |
Alemtuzumab |
For multiple sclerosis and used off-label for allogeneic BMT and peripheral blood SCT |
06.06.02 |
Alendronic acid |
Not a first line option.
For use only in patients unable to swallow conventional bisphosphonate tablets, and unwilling/unsuitable for treatment with parenteral options. |
06.06.02 |
Alendronic acid |
|
09.06.04 |
Alfacalcidol One-Alpha® |
|
A2.03.01 |
Alfamino® |
Ordered through main stores
400g |
04.07.02 |
Alfentanil |
|
15.01.04.03 |
Alfentanil |
Use outside of theatres for palliative care only
|
02.12 |
Alirocumab Praluent® |
|
13.05.01 |
Alitretinoin |
Specialist prescribing only.
Routinely reimbursed by CCG if NICE TA177 eligibility criteria fulfilled.
IFR application required for exceptional use. |
10.01.04 |
Allopurinol |
|
04.07.04.01 |
Almotriptan |
Second line oral triptan |
06.01.02.03 |
Alogliptin |
|
09.06.05 |
Alpha Tocopheryl Acetate Vitamin E |
Injection is unlicensed |
07.04.05 |
Alprostadil Viridal Duo®; Caverject® |
Viridal Duo® brand preferred for initiation at UHS.
Annotate FP10 prescriptions with 'SLS' for erectile dysfunction
|
02.10.02 |
Alteplase Actilyse®; Actilyse Cathflo® |
Also for pulmonary emboli
Actilyse Cathflo® 2mg only for clearing blocked central venous catheters |
13.12 |
Aluminium chloride hexahydrate 20% |
Self Care Medicine. Can be purchased OTC.
|
09.05.02.02 |
Aluminium Hydroxide Alu-Cap® |
|
04.09.01 |
Amantadine |
|
02.05.01 |
Ambrisentan |
For patients managed under a shared care agreement with the Royal Brompton Hospital only |
10.02.01 |
Amifampridine base (3,4-diaminopyridine) |
unlicensed
For Lambert-Eaton myasthenic Syndrome |
05.01.04 |
Amikacin |
|
02.02.03 |
Amiloride Hydrochloride |
|
03.01.03 |
Aminophylline |
|
03.01.03 |
Aminophylline |
MR tab for existing patients only |
02.03.02 |
Amiodarone |
|
02.03.02 |
Amiodarone |
|
04.02.01 |
Amisulpride |
|
04.03.01 |
Amitriptyline |
May also be used off-label for hypersalivation |
04.07.03 |
Amitriptyline |
For neuropathic pain in accordance with NICE Guidelines
Off-label use
|
04.07.04.02 |
Amitriptyline |
Off label use |
02.06.02 |
Amlodipine |
For hypertension; or angina if on betablocker |
13.10.02 |
Amorolfine 5% |
For mild, distal fungal nail injections in up to 2 nails.
Can be purchased OTC (Pharmacy only). |
05.01.01.03 |
Amoxicillin |
for patients with chronic low back pain associated with Modic type 1 changes
|
05.02.03 |
Amphotericin |
|
05.02.03 |
Amphotericin e.g. Abelcet® AmBisome® |
Specify brand |
11.03.02 |
Amphotericin |
unlicensed
|
09.01.04 |
Anagrelide Xagrid® |
Consultant haematologist recommendation only
|
10.01.03 |
Anakinra Kineret® |
Restricted as per commissioning policies.
|
08.03.04.01 |
Anastrozole |
|
12.03.01 |
Antacid with oxetacaine |
unlicensed special
For treatment of symptoms of oral mucositis and oesophageal lesions causing painful swallowing when recommended by cancer care specialist only.
Replaces Mucaine suspension (discontinued) |
11.04.02 |
Antazoline with xylometazoline Otrivine-Antistin® |
|
14.05.03 |
Anti-D (Rh0) Immunoglobulin |
|
08.02.02 |
Antithymocyte immunoglobulin (rabbit) |
|
01.07.01 |
Anusol ® |
Self Care Medicine
|
01.07.02 |
Anusol-HC |
|
02.08.02 |
Apixaban Eliquis®)(AF/VTE |
|
02.08.02 |
Apixaban Eliquis®)(Orthopaedic prophylaxis |
|
04.09.01 |
Apomorphine |
Consultant initiated in severe disease |
11.08.02 |
Apraclonidine Iopidine® |
Note: different licensed indications for different strengths (refer to SPCs).
1% unit dose eye drops are preservative-free.
|
10.01.03 |
Apremilast |
|
13.05.03 |
Apremilast |
|
04.06 |
Aprepitant Emend® |
For chemotherapy-induced nausea/vomiting
Liquid for chemotherapy-induced nausea/vomiting in children 6months - 12years |
02.11 |
Aprotinin Trasylol® |
Restricted to use by Cardio-thoracic anaesthetist only
|
A2.03.01 |
Aptamil® 1 |
Ordered through main stores
900g |
A2.03.01 |
Aptamil® 1 ready to feed |
Ordered through main stores |
A2.03.01 |
Aptamil® Pepti 1 |
Ordered via main stores |
13.02.01 |
Aqueous Cream |
Not recommended by dermatology specialists. Consider alternative emollients, e.g. ZeroAQS (does not contain SLS).
|
01.06.03 |
Arachis Oil |
|
02.08.01 |
Argatroban Exembol® |
Option for patients in critical care areas with heparin-induced thrombocytopenia |
04.02.01 |
Aripiprazole |
|
04.02.02 |
Aripiprazole Abilify Maintena® |
Secondary psychiatric care only
For intramuscular injection
|
04.02.01 |
Aripiprazole 7.5mg/ml Abilify® |
Specialist use only by Southern Health in accordance with rapid tranquilisation guidelines.
|
08.01.05 |
Arsenic trioxide |
|
05.04.01 |
Artemether with lumefantrine |
For acute uncomplicated P.falciparum malaria or as oral step down treatment following IV artesunate |
05.04.01 |
Artesunate |
unlicensed
for severe or complicated P.falciparum malaria
|
09.06.03 |
Ascorbic Acid Vitamin C |
|
09.06.03 |
Ascorbic Acid Vitamin C |
Effervescent tablet for mouthcare only |
02.09 |
Aspirin |
|
02.09 |
Aspirin |
injection is unlicensed
|
04.07.01 |
Aspirin |
EC tablets are not formulary |
04.07.04.01 |
Aspirin |
Soluble or dispersible form preferred +/- metoclopramide |
10.02 |
Ataluren Translarna® |
For use in line with NHSE specialised commissioning criteria |
05.03.01 |
Atazanavir |
|
05.03.01 |
Atazanavir sulfate/cobicistat Evotaz® |
As per NHSE specialised commissioning circular 1614 |
02.04 |
Atenolol |
|
02.04 |
Atenolol |
|
08.01.05 |
Atezolizumab |
|
04.04 |
Atomoxetine Strattera® |
|
02.12 |
Atorvastatin |
|
07.01.03 |
Atosiban |
|
05.04.08 |
Atovaquone |
|
11.05 |
Atropine |
Preservative-free unit dose preparations (Minims®) are the preferred formulation in primary care.
May also be used off-label by sublingual administration for hypersalivation.
1% multi dose eye drop solution: Hospital only (due to high cost).
Primary care recommended to use Minims formulation. |
15.01.03 |
Atropine |
|
09.01.04 |
Avatrombopag Doptelet® |
Expected date of UK availability November 2020
|
08.01.05 |
Avelumab Bavencio® |
Also available via MHRA EAMS (1 Sept 2020) for off label use in adults with advanced urothelial carcinoma that has not progressed after an initial course of chemotherapy. |
07.04.05 |
Aviptadil + phentolamine Invicorp® |
Specialist initiation. Second line to alprostadil |
08.01.05 |
Axitinib |
|
08.01.03 |
Azacitidine |
|
08.02.01 |
Azathioprine |
Liquid and capsules (10mg) are unlicensed
|
08.02.01 |
Azathioprine |
|
10.01.03 |
Azathioprine |
Liquid and capsules (10mg) are unlicensed
|
13.05.03 |
Azathioprine dermatology |
|
13.06.01 |
Azelaic acid 20% Skinoren® |
Alternative if benzoyl peroxide not tolerated
|
12.02.01 |
Azelastine and fluticasone Dymista |
Third line therapy for allergic rhinitis where response to treatment with other therapies, including combination of oral antihistamines and intranasal corticosteroids, was inadequate or not tolerated |
05.01.05 |
Azithromycin |
|
05.01.05 |
Azithromycin |
|
11.03.01 |
Azithromycin |
Ophthalmology only
|
05.01.02.03 |
Aztreonam |
To be used in line with NHSE specialised commissioning policy |
03.01.05 |
Babyhaler® |
|
10.02.02 |
Baclofen |
|
11.09 |
Balanced salt solution |
|
11.99.99.99 |
Balanced salt solution |
|
10.01.03 |
Baricitinib Olumiant® |
|
13.05.03 |
Baricitinib Olumiant® |
|
08.02 |
Basiliximab Simulect® |
|
08.02.04 |
BCG bladder instillation |
|
14.04 |
BCG vaccine diagnostic agent |
unlicensed
|
14.04 |
BCG vaccine Intradermal |
|
03.02 |
Beclometasone and formoterol Fostair® |
Prescribing by brand name recommended
200/6 strength licensed for asthma only, not for COPD |
03.02 |
Beclometasone dipropionate |
MHRA Drug Safety Update July 2008: prescribe CFC-free beclometasone metered-dose inhalers by brand name to reduce the risk of dosing errors
Note: Potencies and dosing recommendations may vary between brands. Refer to product SPC or BNF for more detailed advice.
MDI brands of choice in the Southampton locality are Soprobec (equivalent to Clenil brand) and Kelhale (equivalent to Qvar brand).
Kelhale brand is not licensed in children under 18 years.
|
12.02.01 |
Beclometasone Dipropionate |
First line for adults in nasal allergy |
03.02 |
Beclometasone/formoterol/glycopyrronium Trimbow® |
Prescribing by brand name recommended
|
05.01.09 |
Bedaquiline Sirturo® |
For specialist use only in line with NHS Engand Clinical Commissioning Policy (170132P).
|
03.04.02 |
Bee/Wasp venom allergen extracts Alutard SQ® |
Pharmalgen brand has been discontinued but may be supplied for selected patients when Alutard brand is not suitable.
|
10.01.03 |
Belimumab Benlysta® |
|
08.01.01 |
Bendamustine |
|
02.02.01 |
Bendroflumethiazide |
|
04.02.01 |
Benperidol Anquil® |
Southern Health use only
|
03.04.02 |
Benralizumab Fasenra® |
|
05.01.01.01 |
Benzathine benzylpenicillin |
Special Use by Sexual Health Clinics (Solent NHS Trust) ONLY
For treatment of syphilis as recommended in BASHH Guidelines 2015
The preparation is strictly for deep intramuscular injection
|
03.08 |
Benzoin tincture, compound |
|
13.06.01 |
Benzoyl Peroxide |
Self Care Medicine
|
12.03.01 |
Benzydamine Difflam® |
Available OTC
|
05.01.01.01 |
Benzylpenicillin sodium Penicillin G |
|
03.05.02 |
Beractant |
|
03.04.03 |
Berotralstat |
For the treatment of hereditary angioedema
Specialist use only. Available via MHRA EAMS application for eligible patients.
MHRA EAMS (Feb 2021): Berotralstat in the treatment of hereditary angioedema |
04.06 |
Betahistine Dihydrochloride |
For prophylaxis in proven Ménière’s disease |
09.08.01 |
Betaine |
unlicensed
|
06.03.02 |
Betamethasone |
For use as a mouthwash only |
06.03.02 |
Betamethasone |
|
11.04.01 |
Betamethasone |
|
12.01.01 |
Betamethasone 0.1% |
|
12.01.01 |
Betamethasone 0.1% with neomycin 0.5% Betnesol N® |
A first-line option for acute otitis externa (refer to South Central Antimicrobial Network Guidelines for Antibiotic Prescribing in the Community 2018) |
12.03.01 |
Betamethasone 500microgram |
Use for treatment of oral ulceration or inflammation is off label. For use as a mouthwash only - not to be swallowed.
|
11.04.01 |
Betamethasone and neomycin Betnesol N® |
|
13.04 |
Betamethasone dipropionate 0.05% with salicylic acid 2% Diprosalic® |
|
13.04 |
Betamethasone dipropionate 0.05% with salicylic acid 3% Diprosalic® |
|
12.02.01 |
Betamethasone eye/ear/nose drops |
|
13.04 |
Betamethasone valerate 0.025% Betnovate-RD® |
|
13.04 |
Betamethasone valerate 0.1% Betacap® |
|
13.04 |
Betamethasone valerate 0.1% |
|
13.04 |
Betamethasone valerate 0.1% with fusidic acid 2% Fucibet® |
For short-term use
|
13.04 |
Betamethasone valerate 0.1% with neomycin 0.5% |
For short-term use
|
11.06 |
Betaxolol |
Not a first line choice.
Unit dose drops only for patients allergic/intolerant of preservative, or high risk of developing allergy
|
08.01.05 |
Bevacizumab Avastin® |
For use in line with CDF criteria.
Commissioned by NHS England for neurofibromatosis by NHS England as per national protocol (see NF2 service specification) at specialist centres only. |
02.12 |
Bezafibrate |
Consider only when a statin or other treatments are contra-indicated or not tolerated
Also approved for off-label use for the treatment of primary biliary cholangitis
|
08.03.04.02 |
Bicalutamide |
|
05.03.01 |
Bictegravir / emtricitabine / tenofovir-alafenamide Biktarvy ® |
Specialist only, in line with NHSE Clinical Commissioning Policy 170131P |
11.06 |
Bimatoprost |
Not a first line choice
Unit dose drops only for patients allergic/intolerant of preservatives, or high risk of developing allergy
Eyreida® 0.3mg/ml preservative free eye drop solution: Consider as a more cost-effective alternative other unit drop preparations.
|
11.06 |
Bimatoprost with timolol Ganfort® |
Not a first line choice
Unit dose drops only for patients allergic/intolerant of preservatives, or high risk of developing allergy
Eyzeetan® 0.3mg/ml+5mg/ml preservative free eye drop solution: Consider as a more cost-effective alternative other unit drop preparations.
|
12.03.05 |
Biotene Oralbalance ® |
|
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
|
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix |
|
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
|
06.01.01.02 |
Biphasic Isophane Insulin 25 Insuman® Comb 25 |
|
12.04 |
BIPP gauze |
|
01.06.02 |
Bisacodyl |
|
02.04 |
Bisoprolol |
Heart failure - first line |
02.08.01 |
Bivalirudin Angiox® |
|
08.01.02 |
Bleomycin |
|
08.01.05 |
Blinatumomab |
|
07.02.02 |
Boric acid |
unlicensed
Specialist use by sexual health clinics (Solent NHS Trust) ONLY.
Treatment of chronic/recurrent vaginal candida for which other treatments (inc.azoles,clotrimazole and nystatin) have failed |
08.01.05 |
Bortezomib |
|
02.05.01 |
Bosentan Tracleer® |
For patients managed under a shared care agreement with the Royal Brompton Hospital only |
08.01.05 |
Bosutinib |
|
14.04 |
Botulinum antitoxin |
Specialist clinics only |
01.02 |
Botulinum neurotoxin type A Xeomin® |
|
01.07.04 |
Botulinum toxin type A |
unlicensed for anal fissures
Specify brand |
04.07.04.02 |
Botulinum Toxin Type A |
Specify brand |
04.09.03 |
Botulinum Toxin Type A |
Specify brand and indication
Restricted use - discuss with directorate pharmacist
|
13.12 |
Botulinum toxin type A |
Dermatology only. For severe hyperhidrosis.
|
08.01.05 |
Brentuximab vedotin |
|
08.01.05 |
Brigatinib Alunbrig® |
|
11.06 |
Brimonidine |
|
13.06.01 |
Brimonidine |
For patients with rosacea who have failed to respond to, or are intolerant of, other options, or have psychological distress due to persistent redness.
|
11.06 |
Brimonidine with timolol |
|
11.06 |
Brinzolamide |
|
11.06 |
Brinzolamide with brimonidine Simbrinza® |
Not a first line option |
11.06 |
Brinzolamide with timolol Azarga® |
Not a first line option |
04.08.01 |
Brivaracetam Briviact® |
For specialist initiation. Use restricted to selected patients. (e.g. inadequate seizure control or where other antiepileptic drugs are contraindicated, not tolerated or inappropriate)
|
13.05.03 |
Brodalumab |
|
11.08.02 |
Brolucizumab Beovu® |
|
04.09.01 |
Bromocriptine |
Not a first line option in Parkinson’s disease |
06.07.01 |
Bromocriptine |
|
01.05.02 |
Budesonide |
|
03.02 |
Budesonide |
Prescribing by brand name recommended
|
01.05.02 |
Budesonide 3mg Budenofalk® |
For ileo-caecal disease |
01.05.02 |
Budesonide 9mg Cortiment® |
For ulcerative colitis |
03.02 |
Budesonide and formoterol |
Prescribing by brand name recommended
|
02.02.02 |
Bumetanide |
|
15.02 |
Bupivacaine 0.1% and fentanyl 2microgram/ml epidural |
Obstetrics only
|
15.02 |
Bupivacaine 0.15% and fentanyl 2microgram/ml epidural |
|
15.02 |
Bupivacaine Hydrochloride |
0.125%, 0.25% and 0.5% |
15.02 |
Bupivacaine Hydrochloride 5mg with Glucose 80mg/ml Marcain Heavy® |
|
04.10.03 |
Buprenorphine |
Not initiated in UHS |
04.10.03 |
Buprenorphine Espranor® |
Not initiated in UHS
Espranor is not interchangeable with other buprenorphine products.
|
04.07.02 |
Buprenorphine 35-70microgram/hour 96hour patch |
Prescribe by brand name |
04.07.02 |
Buprenorphine 5-20microgram/hour weekly patch |
Prescribe by brand name |
04.10.03 |
Buprenorphine and Naloxone Suboxone® |
Not initiated in UHS |
04.10.02 |
Bupropion Hydrochloride Zyban® |
As part of a smoking cessation programme. |
09.08.01 |
Burosumab Crysvita® |
Specialist use only in accordance with NICE HST8 guidance
|
06.07.02 |
Buserelin |
|
04.01.02 |
Buspirone Hydrochloride |
|
08.01.01 |
Busulfan |
injection for BMT only |
03.04.03 |
C1 esterase inhibitor Berinert® |
For use as per commissioning criteria set by NHS England
|
03.04.03 |
C1 esterase inhibitor Cinryze® |
For use as per commissioning criteria set by NHS England
Homecare use only
|
08.01.05 |
Cabazitaxel |
|
04.09.01 |
Cabergoline |
Not a first line option in Parkinson’s disease |
06.07.01 |
Cabergoline 500microgram Dostinex® |
Hyperprolactinaemia |
08.01.05 |
Cabozantinib Cabometyx® |
|
13.05.02 |
Cade oil & salicylic acid |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
03.01.03 |
Caffeine citrate |
Neonatal unit only
|
13.03 |
Calamine BP |
|
13.05.02 |
Calcipotriol 50mcg/g |
|
13.05.02 |
Calcipotriol with betamethasone |
|
06.06.01 |
Calcitonin (salmon) / Salcatonin |
|
09.06.04 |
Calcitriol |
|
09.05.02.02 |
Calcium acetate and magnesium carbonate, heavy Osvaren® |
For hyperphosphataemia of chronic renal failure in patients undergoing dialysis |
09.06.04 |
Calcium and colecalciferol (vitamin D3) |
Chewable tablets first-line. Effervescent and film-coated tablets reserved to aid administration in those unable to take chewable tablets.
Note that different formulations have different amounts of colecalciferol and calcium.
Choose brand with lowest acquisition cost and prescribe by brand name to avoid confusion.
Preferred brands in primary care: Accrete D3 or TheiCal D3 |
09.05.01.01 |
Calcium carbonate |
Chewable tablets first-line.
Effervescent tablets reserved to aid administration in those unable to take chewable tablets.
Choose brand with lowest acquisition cost and prescribe by brand name to avoid confusion.
Refer to section 9.6.4 for calcium and vitamin D3. |
09.05.02.02 |
Calcium carbonate |
unlicensed
|
09.05.02.02 |
Calcium Carbonate Adcal® |
|
09.05.01.01 |
Calcium carbonate and calcium lactate gluconate Calvive 1000® |
Formerly Sandocal®
Chewable tablets first line. |
09.05.01.01 |
Calcium Chloride |
|
08.01 |
Calcium Folinate |
folinic acid rescue |
09.05.01.01 |
Calcium Gluconate |
|
18 |
Calcium gluconate 2.5% gel/10% injection |
|
09.05.01.01 |
Calcium lactate + calcium gluconate Alliance Calcium Syrup® |
0.51mmol/ml of Calcium
Specialist recommendation for paediatric patients only.
Licensed as a nutritional supplement, not a medicine.
Primary care to prescribe by brand name. |
09.02.01.01 |
Calcium polystyrene sulfonate Calcium Resonium® |
Powder for oral or rectal suspension
|
A2.04.01.02 |
Calogen ® |
Not held in stock but available to order through pharmacy
200ml/500ml
Strawberry/Neutral |
A2.04.01.02 |
Calogen Extra® |
6 x 40ml stocked in pharmacy |
13.07 |
Camellia sinensis (green tea) leaf extract Catephen 10% ® |
For use by sexual health clinics (Solent NHS Trust) ONLY
For the cutaneous treatment of external genital and perianal warts in immunocompetent patients (adults) when other treatments have failed |
13.08.02 |
Camouflage cosmetics |
As advised by specialist service.
Borderline substances (ACBS). |
06.01.02.03 |
Canagliflozin |
Supported for use in accordance with published NICE TA guidance (see links below) and recommendations in NG28 Type 2 diabetes: management
Note: Canagliflozin for treating diabetic kidney disease is awaiting NICE appraisal (link here). |
02.05.05.02 |
Candesartan |
|
04.08.01 |
Cannabidiol Epidyolex® |
Registered specialist only. See NICE NG144 (section 1.5) for details on who should prescribe.
Schedule 5 controlled drug. |
10.02.02 |
Cannabis extract Sativex® |
Restricted use.
Use is supported only for spasticity in patients with multiple sclerosis in accordance with NICE guidelines NG144.
Must be initiated and supervised by a physician with specialist expertise in treating spasticity due to multiple sclerosis.
Shared care guidance can be found here |
13.09 |
Capasal® Therapeutic |
Salicylic acid 0.5% w/w; coconut oil 1% w/w; distilled coal tar 1% w/w.
|
08.01.03 |
Capecitabine |
|
09.01 |
Caplacizumab Calblivi® |
|
10.03.02 |
Capsaicin Qutenza® |
Only for post herpetic neuralgia where other pain relief is inadequate
|
10.03.02 |
Capsaicin 0.025% Zacin® |
|
02.05.05.01 |
Captopril |
Child Health and for patients particularly at risk of hypotension
|
02.05.05.01 |
Captopril |
Child Health and for patients particularly at risk of hypotension
|
04.07.03 |
Carbamazepine |
|
04.08.01 |
Carbamazepine |
For partial seizures and secondary generalised tonic-clonic seizures |
06.02.02 |
Carbimazole |
|
03.07 |
Carbocisteine |
|
11.08.01 |
Carbomer polyacrylic acid |
To be used in line with DPC dry eye guidelines (link below).
Clinitas® Gel preferred at UHS |
08.01.05 |
Carboplatin |
|
07.01.01 |
Carboprost |
|
09.02.02 |
Cardioplegia Plegivex® |
|
08.01.05 |
Carfilzomib |
|
11.08.01 |
Carmellose sodium |
To be used in line with DPC dry eye guidelines (link below).
Note: Optive®/Optho-lique® brands contain a gentle preservative so may be an option if patient is allergic to commonly-used preservatives |
11.08.01 |
Carmellose sodium |
To be used in line with DPC dry eye guidelines (link below)
Only for patients allergic/intolerant of preservatives or at high risk of developing allergy
May be prescribed as unit dose (single use) eye drops or multi-dose bottle (various brands available - refer to Drug Tariff for current prices in primary care). |
08.01.01 |
Carmustine |
Injection is unlicensed
|
A2.05.02 |
Carobel, Instant ® |
Ordered via main stores |
02.04 |
Carvedilol |
Heart failure - second line |
05.02.04 |
Caspofungin |
Specialist use only
|
05.01.02.01 |
Cefaclor |
|
05.01.02.01 |
Cefalexin |
|
05.01.02.01 |
Cefazolin |
Use restricted to Microbiology recommendation only for MSSA bacteraemia in patients with mild penicillin allergy who are not suitable for treatment with flucloxacillin.
SPC and PIL available on MHRA website. |
05.01.02.01 |
Cefiderocol Fetcroja® |
Microbiology recommendation only
|
05.01.02.01 |
Cefixime |
|
05.01.02.01 |
Cefotaxime |
|
05.01.02.01 |
Cefoxitin |
Unlicensed
Microbiology recommendation only for mycobactrium abcessus respiratory infection in cystic fibrosis
|
05.01.02.01 |
Ceftaroline |
Microbiology recommendation only
|
05.01.02.01 |
Ceftazidime |
|
05.01.02.01 |
Ceftazidime/avibactam |
restricted to microbiology approval/recommendation only
|
05.01.02.01 |
Ceftolozane/tazobactam Zerbaxa® |
restricted to microbiology approval/recommendation only
|
05.01.02.01 |
Ceftriaxone |
|
05.01.02.01 |
Cefuroxime |
|
11.03.01 |
Cefuroxime |
unlicensed
Ophthalmology only
|
10.01.01 |
Celecoxib |
|
08.02.04 |
Cemiplimab Libtayo |
|
08.01.05 |
Ceritinib |
|
10.01.03 |
Certolizumab Pegol Cimzia® |
|
13.05.03 |
Certolizumab pegol Cimzia® |
|
03.04.01 |
Cetirizine |
|
13.02.01 |
Cetraben® |
Consider ExCetra cream as more cost effective alternative to Cetraben cream
Ointment also suitable for use as a soap substitute or as bath additive. |
13.09 |
Cetrimide and undecenoic acid Ceanel Concentrate® |
|
06.07.02 |
Cetrorelix Cetrotide® |
|
08.01.05 |
Cetuximab |
|
04.01.01 |
Chloral Hydrate 500mg in 5mL |
unlicensed
|
04.01.01 |
Chloral Hydrate Suppositories |
unlicensed
|
08.01.01 |
Chlorambucil |
|
05.01.07 |
Chloramphenicol |
Capsules on microbiology advice only
|
11.03.01 |
Chloramphenicol |
Use ointment in children under 2 years: Avoid using eye drop preparations in those under 2 years due to boric acid content. Please prescribe/supply ointment preparation instead in this age group until national guidance is available. Please see advice on prescribing boric Acid/ borate' containing products in children.
Eykappo® 5mg/ml preservative free eye drop solution: Consider as a more cost-effective alternative other unit drop preparations.
Chloramphenicol 0.5% eye drops (in max. pack size 10 mL) and 1% eye ointment (in max. pack size 4 g) can be sold to the public for treatment of acute bacterial conjunctivitis in adults and children over 2 years; max. duration of treatment 5 days. Conditions for which over the counter items should not routinely be prescribed in primary care.
|
12.01.01 |
Chloramphenicol 5% |
|
04.10.01 |
Chlordiazepoxide |
For alcohol withdrawl
UHS users see local guideline |
11.03.01 |
Chlorhexidine |
unlicensed
Ophthalmology only
|
12.03.04 |
Chlorhexidine |
Available over the counter in primary care |
13.11.02 |
Chlorhexidine |
From NHS Logistics. |
07.04.04 |
Chlorhexidine 0.02% |
|
13.11.03 |
Chlorhexidine and cetrimide Tisept® |
From NHS Logistics. |
13.11.03 |
Chlorhexidine and cetrimide |
|
13.11.02 |
Chlorhexidine gluconate 0.05% |
From NHS Logistics. |
13.11.02 |
Chlorhexidine gluconate 0.5% |
From NHS Logistics. |
13.11.02 |
Chlorhexidine gluconate 1% |
|
13.11.02 |
Chlorhexidine gluconate 4% |
From NHS Logistics |
12.02.03 |
Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® |
|
05.04.01 |
Chloroquine |
Supported only for licensed indications ( not on NHS for malaria prevention)
Not for use in Covid-19 treatment/prevention outside of clinical trials (see links below). Seek further advice from infection control specialist/pharmacy team. |
02.02.01 |
Chlorothiazide |
unlicensed
Child Health only
|
03.04.01 |
Chlorphenamine |
|
04.02.01 |
Chlorpromazine |
|
12.03.01 |
Choline salicylate Bonjela® |
Available OTC
For adults and children over 16 years only
|
06.05.01 |
Choriogonadotropin Alfa |
|
06.05.01 |
Chorionic Gonadotrophin HCG |
|
03.02 |
Ciclesonide |
Specialist initiation only. For add on treatment in severe asthma as a steroid sparing agent.
|
08.02.02 |
Ciclosporin |
Red for renal transplant
Amber for all other indications
Specify brand |
08.02.02 |
Ciclosporin |
|
10.01.03 |
Ciclosporin |
Specify brand |
13.05.03 |
Ciclosporin dermatology |
Prescribe by brand name |
11.04.02 |
Ciclosporin 0.1% Verkazia® |
1mg/ml.
Ophthalmology specialist initiation. Prescribe by brand name (different licensed indication to Ikervis® brand).
|
11.08.01 |
Ciclosporin 0.1% Ikervis® |
1mg/ml
Prescribe by brand name (different licensed indication to Verkazia® brand) |
11.08.01 |
Ciclosporin 0.2% |
Unlicensed formulation. Restricted use - only when licensed formulation not suitable or unavailable.
|
05.03.02.02 |
Cidofovir |
For use as per commissioning criteria set by NHS England
|
01.03.01 |
Cimetidine |
For palliative care use only, or as an alternative H2-antagonist when ranitidine is not available, and a proton pump inhibitor is not suitable.
Check for interactions before prescribing.
|
09.05.01.02 |
Cinacalcet Mimpara® |
Endocrinologist use only
|
04.06 |
Cinnarizine |
For labyrinthine vertigo or acute treatment of Ménière’s disease |
05.01.12 |
Ciprofloxacin |
|
05.01.12 |
Ciprofloxacin |
|
12.01.01 |
Ciprofloxacin 0.3% with dexamethasone 0.1% Cilodex® |
Second line when aminoglycosides should not be used. |
12.01.02 |
Ciprofloxacin 0.3% with dexamethasone 0.1% Cilodex® |
Second line where aminoglycosides should not be used |
15.01.05 |
Cisatracurium Nimbex® |
|
08.01.05 |
Cisplatin |
|
04.03.03 |
Citalopram |
Tablets and oral drops are not dose-equivalent |
08.01.03 |
Cladribine |
|
10.02 |
Cladribine Mavenclad® |
|
05.01.05 |
Clarithromycin |
|
05.01.06 |
Clindamycin |
Liquid is unlicensed
|
05.01.06 |
Clindamycin |
|
05.04.08 |
Clindamycin |
In combination with primaquine (off-label use)
Liquid is unlicensed
|
07.02.02 |
Clindamycin |
|
13.06.01 |
Clindamycin 1% |
|
13.06.01 |
Clindamycin 1% and tretinoin 0.025% |
|
13.06.01 |
Clindamycin with benzoyl peroxide Duac® Once Daily |
|
04.08.01 |
Clobazam |
|
13.04 |
Clobetasol propionate 0.05% |
|
13.04 |
Clobetasol propionate 0.05% with neomycin and nystatin |
Prescribe as generic - Dermovate-NN brand discontinued
|
13.04 |
Clobetasone butyrate 0.05% Eumovate® |
|
13.04 |
Clobetasone butyrate 0.05% with oxytetracycline 3% and nystatin Trimovate® |
Not usually a first-line treatment option. For short-term use only in accordance with product licence (refer to SPC) for treatment of steroid responsive dermatoses where candidal and/or bacterial infection is present, suspected or likely to occur.
Note: nystatin is not effective against dermatophytes and risk of resistance with overuse of topical antibiotics.
Not supported locally for off label use in chronic wound management (see below)
|
05.01.09 |
Clofazimine |
Unlicensed
Specialist microbiology/TB service recommendation only
|
04.01.01 |
Clomethiazole Heminevrin® |
|
06.05.01 |
Clomifene citrate |
|
04.03.01 |
Clomipramine |
|
04.01.02 |
Clonazepam |
Southern Health only
|
04.08.01 |
Clonazepam |
|
04.08.02 |
Clonazepam |
unlicensed
|
02.05.02 |
Clonidine |
Amber Recommended for licensed indications (refer to SmPC for details).
for short-term, off label use in sedation/opioid withdrawal in high care paediatrics in accordance with UHS protocol
|
02.05.02 |
Clonidine Catapres® |
|
02.05.02 |
Clonidine 50micrograms in 5ml |
for short-term, off label use in sedation/opioid withdrawal in high care paediatrics in accordance with UHS protocol; oral solution only for use when tablet formulation not suitable
|
02.09 |
Clopidogrel |
|
07.02.02 |
Clotrimazole |
|
12.01.01 |
Clotrimazole 1% |
|
13.10.02 |
Clotrimazole 1% |
Can be purchased OTC.
|
04.02.01 |
Clozapine |
Specialist use only for treatment resistant schizophrenia
|
13.05.02 |
Coal tar Psoriderm® |
|
13.09 |
Coal tar 4% Polytar® |
|
13.05.02 |
Coal tar 5% Exorex® |
|
13.05.02 |
Coal tar BP |
2%, 5% and 10%
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.09 |
Coal tar extract 5% (alcoholic) Alphosyl 2 in 1® |
|
13.05.02 |
Coal tar solution BP 3.3% with propylene glycol 20% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05.02 |
Coal tar solution BP 5% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05.02 |
Coal tar solution BP 6% & salicylic acid 2% Coal tar Scalp Pomade |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05.02 |
Coal tar solution BP 6% & salicylic acid 6% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05.02 |
Coal tar, salicylic acid & sulphur Sebco ® |
|
02.02.04 |
Co-amilofruse (furosemide and amiloride) |
Only as an aid to compliance |
05.01.01.03 |
Co-Amoxiclav |
|
04.09.01 |
Co-Beneldopa |
|
05.03.01 |
Cobicistat Tybost® |
Specialist only, in line with NHSE Clinical Commissioning Policy F03/P/b
|
11.07 |
Cocaine |
unlicensed
|
12.03.01 |
Cocaine 5% |
Unlicensed
|
15.02 |
Cocaine 5% |
|
04.09.01 |
Co-Careldopa Duodopa® |
For use as per specialist commissioning criteria set by NHS England
|
04.09.01 |
Co-Careldopa |
|
04.09.01 |
Co-Careldopa with Entacapone |
|
13.05 |
Coconut oil 25% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.06.02 |
Co-cyprindiol |
|
01.06.02 |
Co-danthramer |
Only for constipation in terminal illness |
01.06.02 |
Co-danthrusate |
Only for constipation in terminal illness |
03.09.01 |
Codeine Linctus BP |
|
01.04.02 |
Codeine phosphate |
|
04.07.02 |
Codeine phosphate |
suppositories are unlicensed
|
10.01.04 |
Colchicine |
Second line |
09.06.04 |
Colecalciferol Vitamin D3 |
Products that are UK licensed medicines should be prescribed and supplied wherever possible
Local West Hants CCG guidance can be found here |
01.09.02 |
Colesevelam |
Second line to colestyramine for treatment of diarrhoea associated with bile acid malabsorption (off label use) - specialist diagnosis and recommendation only
|
01.09.02 |
Colestyramine powder |
|
02.12 |
Colestyramine powder |
|
05.01.07 |
Colistimethate |
|
05.01.07 |
Colistimethate |
Cancer care only, for gut sterilisation prior to BMT
|
05.01.07 |
Colistimethate |
injection can be nebulised |
10.03.01 |
Collagenase Xiapex® |
Limited usage - contact Care Group Pharmacist |
01.01.01 |
Co-magaldrox Mucogel® |
First line option in primary care |
07.03.01 |
Combined Hormonal Contraceptives TriNovum® |
For existing patients only. No longer routinely recommended |
07.03.01 |
Combined Hormonal Contraceptives Qlaira® |
Specialist only use for exceptionally heavy menstrual bleeding
|
A2.03.01 |
Complete amino acid mix (Nutricia®) |
Ordered through main stores
200g |
09.02.02.01 |
Compound Sodium Lactate BP known as Hartmann's solution |
|
03.04.03 |
Conestat alfa Ruconest® |
For use as per commissioning criteria set by NHS England
|
12.04 |
Co-phenylcaine |
Unlicensed
|
07.03.04 |
Copper intra-uterine devices |
|
06.05.01 |
Corticorelin (corticotrophin-releasing hormone) |
|
05.01.08 |
Co-trimoxazole |
|
05.04.08 |
Co-trimoxazole |
|
14.04 |
COVID-19 Vaccine |
Pfizer-BioNTech mRNA COVID-19 vaccine (BNT162b2)
AstraZeneca’s Covid-19 vaccine (ChAdOx1-S [recombinant])
Please see our home page: 'Covid-19 Resources' for useful guidance links.
|
A2.03.01 |
Cow and Gate® 1st infant milk |
Ordered through main stores
70mls x 24 |
A2.03.01 |
Cow and Gate® Pepti-Junior |
Ordered via main stores |
08.01.05 |
Crisantaspase |
|
08.01.05 |
Crizotinib |
|
13.03 |
Crotamiton |
For itch after scabies
|
13.05.02 |
Crude coal tar in white soft paraffin |
|
09.01.02 |
Cyanocobalamin (vitamin B12) |
For use only when patients are unable to receive hydroxocobalamin injections (e.g. during COVID-19).
Self Care Medicine: Patients should be recommended to self purchase unless they meet the exception criteria outlined in the NHS England Guidance on conditions for which over the counter items should not routinely be prescribed in primary care (section 4.1.2 Vitamins and Minerals)
|
09.01.02 |
Cyanocobalamin (vitamin B12) |
For use only when patients are unable to receive hydroxocobalamin injections (e.g. during COVID-19).
Self Care Medicine: Not usually suitable for prescribing on the NHS. Patients should be recommended to self purchase unless they meet the exception criteria outlined in the NHS England Guidance on conditions for which over the counter items should not routinely be prescribed in primary care (section 4.1.2 Vitamins and Minerals)
|
04.06 |
Cyclizine |
For oral, intramuscular or subcutaneous administration. Note: subcutaneous administration is off label but is established practice in palliative care.
For intravenous administration. Due to safety concerns, intravenous use of cyclizine at UHS is restricted to short-term (i.e. single dose) only.
|
11.05 |
Cyclopentolate |
Unit dose drops are preservative-free. |
08.01.01 |
Cyclophosphamide |
|
05.01.09 |
Cycloserine |
Specialist microbiology/TB service recommendation only
|
03.04.01 |
Cyproheptadine |
Paediatric oncology only
|
06.04.02 |
Cyproterone Acetate |
|
08.03.04.02 |
Cyproterone acetate |
|
08.01.03 |
Cytarabine |
|
02.08.02 |
Dabigatran Pradaxa®) (AF/VTE |
|
02.08.02 |
Dabigatran Pradaxa®) (Orthopaedic prophylaxis |
|
08.01.05 |
Dabrafenib |
|
08.01.05 |
Dacarbazine |
|
05.03.03.02 |
Daclatasvir |
|
08.01.05 |
Dacomitinib Vizimpro® |
|
08.01.02 |
Dactinomycin |
unlicensed
|
05.01.07 |
Dalbavancin |
For use only when recommended by microbiology/infectious disease consultant
|
02.08.01 |
Danaparoid Orgaran® |
For thromboprophylaxis when history of heparin-induced thrombocytopenia |
06.07.02 |
Danazol unlicensed import |
For long-term prophylaxis of hereditary angioedema.
|
10.02.02 |
Dantrolene |
|
15.01.08 |
Dantrolene Sodium |
Notify consultant IMMEDIATELY diagnosis suspected |
06.01.02.03 |
Dapagliflozin |
supported for type 2 diabetes in accordance with NICE technology appraisal guidance (see below) and recommendations in NG28 Type 2 diabetes: management
supported for type 1 diabetes in accordance with NICE technology appraisal guidance (see below)
(NICE TA679) for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
-
angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
-
sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.
primary care guidance currently under development by UHS
|
07.04.06 |
Dapoxetine Priligy® |
Supported by DPC Feb 2014 for use when recommended by a specialist for select patients who have failed or are not considered suitable for other treatment options.
Note: for patients with concomitant depression/anxiety, 'off label' use of SSRIs would be preferred. |
05.01.10 |
Dapsone |
|
05.04.08 |
Dapsone |
|
05.01.07 |
Daptomycin |
Specialist use only
|
08.01.05 |
Daratumumab Darzalex® |
|
09.01.03 |
Darbepoetin Alfa Aranesp® |
|
07.04.02 |
Darifenacin |
|
08.03.04.02 |
Darolutamide Nubeqa® |
|
05.03.01 |
Darunavir |
|
05.03.01 |
Darunavir/cobicistat Rezolsta® |
As per NHSE specialised commissioning circular 1614 |
05.03.01 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate Symtuza® |
Specialist only, in line with NHSE Clinical Commissioning Policy F03/P/b
|
05.03.03.02 |
Dasabuvir |
|
08.01.05 |
Dasatinib |
|
08.01.02 |
Daunorubicin |
|
09.01.03 |
Deferasirox Exjade® |
For use as per commissioning criteria set by NHS England |
09.01.03 |
Deferiprone Ferriprox® |
For use as per commissioning criteria set by NHS England |
02.08.01 |
Defibrotide |
unlicensed
|
08.03.04.02 |
Degarelix Firmagon® |
|
09.06.07 |
DEKAs Essential/DEKAs Plus |
Vitamin and mineral supplements for use when recommended by a specialist in patients with cystic fibrosis.
Specialists to ensure preferred formulation and dose is clearly communicated to primary care prescribers. |
05.01.12 |
Delafloxacin Quofenix® |
Microbiology approval only.
Not to be used as first-line treatment option.
Please ensure to read safety precautions and contra-indications of use as per BNF/SPC. MHRA links can be found below.
|
05.01.09 |
Delamanid Deltyba® |
For specialist use only in line with NHS England Clinical Commissioning Policy (170132P).
|
05.01.03 |
Demeclocycline |
For the treatment of SIADH |
06.06.02 |
Denosumab XGEVA® |
metastases |
06.06.02 |
Denosumab Prolia® |
Osteoporosis.
|
07.02.02 |
Dequalinium chloride Fluomizin® |
Specialist use by Sexual Health Clinics (Solent NHS Trust) ONLY
For treatment of bacterial vaginosis (when other treatments have failed) |
13.02.01 |
Dermol® |
Note: Contains an antimicrobial. Not recommended for long term use.
Also suitable for use as a soap substitute. |
09.01.03 |
Desferrioxamine mesilate |
|
18 |
Desferrioxamine mesilate |
|
15.01.02 |
Desflurane Suprane® |
For bariatric surgery
For use by Consultants, or on approval of a Consultant, for patients with BMI>35kg/m2 undergoing obstetric or gynaecological surgery
|
06.05.02 |
Desmopressin |
|
06.05.02 |
Desmopressin Octim® |
150mcg per metered dose nasal spray for Von Willebrand's disease |
06.05.02 |
Desmopressin (DDAVP) |
|
06.05.02 |
Desmopressin acetate Noqdirna ® |
- For symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults
- Initial prescription and initial sodium monitoring (before initiation and in the first week of treatment) completed by secondary care.
Supported by DPC Dec 2018. Updated agreement on sodium monitoring agreed Feb 2021. |
07.03.02.01 |
Desogestrel 75 microgram |
|
06.03.02 |
Dexamethasone |
Soluble tablets first line at UHS
|
06.03.02 |
Dexamethasone |
For palliative care use
For all other uses
|
11.04.01 |
Dexamethasone |
Eythalm® 1mg/ml preservative free eye drop solution: Consider as a more cost-effective alternative other unit drop preparations.
|
11.04.01 |
Dexamethasone intravitreal implant Ozurdex® |
|
11.04.01 |
Dexamethasone, framycetin, gramicidin Sofradex® |
Green for otitis externa (see section 12.1.1) |
11.04.01 |
Dexamethasone, neomycin and polymyxin B Maxitrol® |
|
12.01.01 |
Dexamethasone/framycetin/gramicidin Sofradex® |
Amber for eye indications (see section 11.4.1) |
12.01.01 |
Dexamethasone/neomycin/acetic acid Otomize® |
|
04.04 |
Dexamfetamine |
|
15.01.04.04 |
Dexmedetomidine Dexdor® |
Neuro ICU consultant only or
Off-label use for awake craniotomy and paediatric laryngotracheobronchoscopy
|
08.01 |
Dexrazoxane Cardioxane® |
Approved only for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines in accordance with NHS England Commissioning Policy.
Note: Savene® brand remains non-formulary
|
04.07.02 |
Diamorphine hydrochloride |
|
04.01.02 |
Diazepam |
|
04.08.02 |
Diazepam epilepsy |
|
10.02.02 |
Diazepam |
|
15.01.04.01 |
Diazepam |
|
06.01.04 |
Diazoxide |
|
10.01.01 |
Diclofenac |
Not a first line NSAID |
10.01.01 |
Diclofenac 50mg in 5ml |
Unlicensed special. Restricted use - short term use for postoperative analgesia in children. Second line to ibuprofen and only when licensed options are not suitable.
|
15.01.04.02 |
Diclofenac sodium 75mg in 3ml |
Restricted to paediatric theatres only, or for adults if ketorolac injection not available.
Refer to product information or Medusa IV guide for instructions on administration. Must be diluted and buffered prior to administration by IV infusion. Not suitable for IV bolus.
Use in children is off label.
|
10.01.01 |
Diclofenac with misoprostol Arthrotec® |
Diclofenac not a first line NSAID.
Consider using a preferred NSAID (e.g. ibuprofen or naproxen) or celecoxib ± gastroprotection (e.g. PPI) as alternative |
05.03.01 |
Didanosine |
|
13.11 |
Didecyldimonium chloride 1% wash Stellisep med |
From NHS logistics |
10.03.02 |
Diethylamine salicylate Algesal® |
Self Care Medicine
|
08.03.01 |
Diethylstilbestrol |
|
13.04 |
Diflucortolone valerate 0.3% Nerisone Forte® |
|
02.01.01 |
Digoxin |
|
02.01.01 |
Digoxin |
|
02.01.01 |
Digoxin specific antibody fragments Digifab® |
|
18 |
Digoxin specific antibody fragments Digifab® |
|
04.07.02 |
Dihydrocodeine |
|
02.06.02 |
Diltiazem 60mg |
Suitable for generic prescribing. |
02.06.02 |
Diltiazem Hydrochloride Zemtard XL® |
For angina if not on beta-blocker
Once daily preparation
Prescribe by brand name |
02.06.02 |
Diltiazem Hydrochloride Viazem XL® |
For angina if not on beta-blocker.
Once daily preparation.
Prescribe by brand name |
18 |
Dimercaprol |
|
08.02.04 |
Dimethyl fumarate Tecfidera® |
|
13.05.02 |
Dimethyl fumarate Skilarence® |
|
07.04.04 |
Dimethyl sulfoxide 50% solution |
unlicensed
Urology specialist only
|
13.10.04 |
Dimeticone |
For head lice.
Self Care Medicine. Can be purchased OTC (e.g. Hedrin®).
|
07.01.01 |
Dinoprostone |
Pessary off-label use at UHS for outpatient induction of labour (see staffnet for guideline) |
07.01.01.01 |
Dinoprostone |
Off-label use |
08.01.05 |
Dinutuximab beta Qarziba® |
|
13.05.03 |
Diphenylcyclopropenone in acetone 0.00001-6.0% w/v |
Dermatology only
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
Topical immunotherapy - highly sensitising. To be applied only by trained professionals. Wear gloves when handling.
|
13.07 |
Diphenylcyclopropenone in acetone 0.00001-6.0% w/v |
Dermatology only
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
Topical immunotherapy - highly sensitising. To be applied only by trained professionals. Wear gloves when handling.
|
14.04 |
Diphtheria, tetanus, acellular pertussis, IPV, HiB and hepatitis B Infanrix Hexa® |
|
13.02.01 |
Diprobase® |
|
02.09 |
Dipyridamole |
Only if opening capsules is inappropriate
Liquid is sugar free |
02.09 |
Dipyridamole |
|
11.99.99.99 |
Disodium edetate 0.37% eye drops |
Unlicensed
|
06.06.02 |
Disodium pamidronate |
|
02.03.02 |
Disopyramide |
|
02.03.02 |
Disopyramide |
|
04.10.01 |
Disulfiram Antabuse® |
|
13.05.02 |
Dithranol |
For short term use
|
13.05.02 |
Dithranol in Lassar's Paste |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
02.07.01 |
Dobutamine |
|
08.01.05 |
Docetaxel |
|
01.06.02 |
Docusate Sodium |
|
05.03.01 |
Dolutegravir |
|
05.03.01 |
Dolutegravir sodium/lamivudine Dovato® |
For specialist use only.
For the treatment of Human Immunodeficiency Virus (HIV-1) infected adults and adolescents over 12 years of age |
05.03.01 |
Dolutegravir sodium/rilpivirine hydrochloride Juluca® |
For the treatment of Human Immunodeficiency Virus (HIV-1) infected adults |
04.06 |
Domperidone |
unlicensed suppositories. Also used off-label for stimulation of lactation (contra-indicated in patients with known cardiac problems).
Short-term use only. No longer indicated as a motility stimulant.
|
04.11 |
Donepezil |
Orodispersible tablets only for patients unable to swallow tablets |
02.07.01 |
Dopamine |
|
03.07 |
Dornase Alfa |
|
11.06 |
Dorzolamide |
|
11.06 |
Dorzolamide preservative-free Eydelto® |
In primary care as a more cost effective alternative to unit dose eye drops. Only for patients allergic/intolerant of preservatives, or high risk of developing allergy
|
11.06 |
Dorzolamide with timolol |
Unit dose drops only for patients allergic/intolerant of preservatives, or high risk of developing allergy
|
11.06 |
Dorzolamide with timolol preservative-free Eylamdo®, Cosopt iMulti® |
In primary care as a more cost effective alternative to unit dose eye drops. Only for patients allergic/intolerant of preservatives, or high risk of developing allergy.
|
13.02.01 |
Doublebase® |
Consider Isomol or Zerodouble as more cost effective alternatives.
May also be applied before washing, showering or bathing. |
15.01.07 |
Doxapram Dopram® |
|
02.05.04 |
Doxazosin |
Not XL (prolonged-release) tablet |
07.04.01 |
Doxazosin |
Modified release tablets are non-formulary |
08.01.02 |
Doxorubicin |
Liposomal is a high cost drug |
05.01.03 |
Doxycycline |
Dispersible tablets only if cannot swallow caps |
05.01.03 |
Doxycycline |
unlicensed
|
05.04.01 |
Doxycycline |
|
13.06.02 |
Doxycycline |
Dispersible tabs only if patient cannot swallow caps.
Second-line to oxytetracycline/lymecycline for acne. |
13.02.02 |
Drapolene® |
|
02.03.02 |
Dronedarone Multaq® |
|
04.06 |
Droperidol |
Prevention and treatment of PONV in paediatrics only (second-line to ondansetron and dexamethasone).
Restricted to anaesthetist use only. Guideline in development.
|
06.01.02.03 |
Dulaglutide Trulicity® |
Once weekly formulation. |
04.07.03 |
Duloxetine |
For neuropathic pain in accordance with NICE Guidelines |
13.08.01 |
Dundee reflectant sunscreens |
Dermatology recommendation only
From British Association Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05.03 |
Dupilumab Dupixent®) (dermatology |
Specialist use only for atopic dermatitis in eligible adult patients (see NICE TA534) - commissioned by CCGs.
Commissioned by NHS England for adolescent patients 12 to 18 years if the patient is seen within a specialist treatment centre (e.g. specialised paediatric dermatology and/or paediatric allergy) and meets the criteria set out in NICE TA534. Also available via MHRA EAMS for patients aged 6 to 11 years with severe atopic dermatitis who are candidates for systemic therapy and where existing therapies are not advisable. Note: use in children
Currently non-formulary for severe asthma (awaiting NICE TA guidance - due Jan 2021)
Currently non-formulary for treating chronic rhinosinusitis with nasal polyps. NICE TA648 - terminated appraisal.
|
08.01.05 |
Durvalumab Imfinzi® |
NICE TA662: Durvalumab in combination for untreated extensive-stage small-cell lung cancer. Terminated appraisal as company withdrew evidence submission
|
09.01.03 |
Eculizumab Soliris® |
for atypical haemolytic uraemic syndrome (see NICE HST1 guidance)
Non-formulary for relapsing NMO (see NICE TA647 terminated appraisal link below).
|
02.08.02 |
Edoxaban Lixiana® |
Due to cost effectiveness this is the first choice DOAC locally for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF). See DPC Anticoagulant Decision Aid.
Note: other DOACs may be used if considered more clinically appropriate. |
05.03.01 |
Efavirenz |
|
05.03.01 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate Atripla® |
|
13.09 |
Eflornithine Vaniqa® |
Only when other available options are inappropriate or ineffective
|
09.01 |
Efmoroctocog alfa Elocta® |
|
05.03.03.02 |
Elbasvir with grazoprevir Zepatier® |
|
A2.01.01.02 |
Elemental 028 ® Extra |
Not held in stock but available to order through pharmacy
100g powder - unflavoured
250ml liquid - Grapefruit/Orange/Pineapple/Summer fruit |
03.07 |
Elexacaftor/tezacaftor/ivacaftor Kaftrio® |
Restricted to patients as per NHS England commissioning policies |
09.01.04 |
Eltrombopag Revolade® |
|
01.04.02 |
Eluxadoline Truberzi® |
|
05.03.01 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate Genvoya® |
Specialist only, in line with NHSE Clinical Commissioning Policies 16043/P and F/03/P/b
|
05.03.01 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate Stribild® |
Specialist only, in line with NHSE Clinical Commissioning Policy F03/P/b
|
09.01.03 |
Emicizumab |
|
06.01.02.03 |
Empagliflozin |
Supported for use in accordance with published NICE TA guidance (see links below) and recommendations in NG28 Type 2 diabetes: management |
05.03.01 |
Emtricitabine |
|
05.03.01 |
Emtricitabine/rilpivirine/tenofovir alafenamide fumarate Odefsey® |
Specialist only, in line with NHSE Clinical commissioning policy 16043/P
|
05.03.01 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate Eviplera® |
Specialist use only. Refer to NHS England Drugs List
|
05.03.01 |
Emtricitabine/tenofovir alafenamide fumarate Descovy® |
Specialist only, in line with NHSE Clinical Commissioning Policy 16043/P
|
05.03.01 |
Emtricitabine/tenofovir disoproxil fumarate |
When Zidovudine/lamivudine is unsuitable
|
13.02.01.01 |
Emulsiderm® Emollient |
Note: contains an antimicrobial. Not recommended for long-term use.
|
13.02.01.01 |
Emulsiderm® Emollient |
Note: contains an antimicrobial. Not recommended for long-term use.
|
13.02.01 |
Emulsifying Ointment |
|
02.05.05.01 |
Enalapril |
|
08.01.05 |
Encorafenib Braftovi® |
|
A2.04.01.02 |
Energivit ® |
Ordered via main stores |
02.08.01 |
Enoxaparin/enoxaparin biosimilar |
Amber for extended thromboprophylaxis
Amber in pregnancy. Shared care guidance can be found here
Green for other recognised indications
Prescribe by brand name and ensure patients are counselled on use of the relevant device. From mid-September 2020 UHS will be using Inhixa brand only.
Arovi, Enoxaparin Becat and Inhixa brands are black triangle
|
04.09.01 |
Entacapone |
Can be used with levodopa preparations to reduce “off-time” in later Parkinson’s disease |
05.03.03.01 |
Entecavir |
|
08.01.05 |
Entrectinib Rozlytrek® |
|
08.03.04.02 |
Enzalutamide Xtandi® |
Note: not recommended for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults, in accordance with NICE TA580 |
13.11.06 |
Eosin 2% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
02.07.02 |
Ephedrine |
|
03.01.01.02 |
Ephedrine |
Also off-label for diabetic neuropathy |
12.02.02 |
Ephedrine |
|
13.02.01 |
Epimax Paraffin-free |
For use only in patients intolerant to paraffin-containing products.
Note: MHRA safety warnings re: fire risks also apply to paraffin-free emollients. |
13.02.01 |
Epimax®/ Diprobase ® |
Also suitable for use as soap substitute.
Epimax first line choice as more cost effective.
|
13.02.01 |
Epimax®/ Epaderm®/ Hydromol® |
Epimax ointment 1st line as more cost effective option and same active ingredients as Epaderm.
For use as emollient/bath additive or as barrier cream. |
08.01.02 |
Epirubicin |
|
02.02.03 |
Eplerenone |
If hormonal side effects on spironolactone
To reduce the risk of CV mortality and morbidity in selected patients after recent MI or with CHF |
09.01.03 |
Epoetin alfa Eprex® |
|
09.01.03 |
Epoetin beta NeoRecormon® |
also for paediatric renal patients |
02.08.01 |
Epoprostenol Flolan® |
|
02.09 |
Eptifibatide Integrilin® |
|
04.07.04.02 |
Erenumab Amiovig® |
140mg strength supported only as per NICE TA
|
09.06.04 |
Ergocalciferol Vitamin D2 |
|
07.01.01 |
Ergometrine Maleate |
|
07.01.01 |
Ergometrine Maleate and Oxytocin Syntometrine® |
|
08.01.05 |
Eribulin |
|
08.01.05 |
Erlotinib |
|
05.01.02.02 |
Ertapenem |
|
06.01.02.03 |
Ertugliflozin |
Supported for use in accordance with published NICE TA guidance (see links below) and recommendations in NG28 Type 2 diabetes: management |
05.01.05 |
Erythromycin |
|
13.06.02 |
Erythromycin |
Not a first-line option in acne.
|
13.06.01 |
Erythromycin 2% with isotretinoin 0.05% |
|
04.03.03 |
Escitalopram |
Third line on specialist advice
Oral drops (Cipralex®) are Non Formulary |
04.08.01 |
Eslicarbazepine Zebinix® |
|
02.04 |
Esmolol |
Critical care only
|
01.03.05 |
Esomeprazole |
Child Health only
|
01.03.05 |
esomeprazole |
Child health only
For children >1 year and >10kg with feeding tubes
Lansoprazole orodispersible tablets preferred in adults with swallowing difficulties/enteral tube administration. |
01.03.05 |
Esomeprazole |
Only for Grade III to IV oesophagitis unresponsive to high dose omeprazole. |
06.04.01.01 |
Estradiol Evorel® |
|
07.02.01 |
Estradiol |
|
07.03.01 |
Estradiol 1.5mg/nomegestrol acetate 2.5mg Zoely® |
Specialist use at Solent NHS Trust only
Each pack contains 24 white active tablets and 4 yellow placebo tablets.
|
06.04.01.01 |
Estradiol and estradiol/norethisterone Evorel® Sequi |
Continuous sequential HRT transdermal delivery systems (TDSs) comprising
a) 4 EVOREL 50 TDSs, each containing:
- 3.2 mg of estradiol hemihydrate
b) 4 EVOREL CONTI TDSs, each containing:
- 3.2 mg of estradiol hemihydrate
- 11.2 mg of norethisterone acetate
|
06.04.01.01 |
Estradiol and estradiol/norethisterone Elleste-Duet® |
Continuous sequential HRT tablet |
06.04.01.01 |
Estradiol hemihydrate Elleste-Solo® |
|
06.04.01.01 |
Estradiol hemihydrate / Dydrogesteron Femoston®/ Femoston-conti® |
|
06.04.01.01 |
Estradiol valerate Progynova® |
|
06.04.01.01 |
Estradiol/norethisterone Evorel® Conti |
Continuous combined HRT |
06.04.01.01 |
Estradiol/norethisterone Elleste-Duet Conti® |
Continuous combined HRT |
07.02.01 |
Estriol Ovestin® |
|
02.11 |
Etamsylate |
Countess Mountbatten House use only
unlicensed
|
10.01.03 |
Etanercept/etanercept biosimilar Enbrel®, Benepali®, Erelzi®) (Rheumatology |
Specify brand
Erelzi is black triangle
|
13.05.03 |
Etanercept/etanercept biosimilar Enbrel®, Benepali®, Erelzi®) (dermatology |
Specify brand.
Benepali and Erelzi are black triangle
|
09.05.01.02 |
Etelcalcetide Parsabiv® |
|
05.01.09 |
Ethambutol |
|
18 |
Ethanol (alcohol) injection |
|
02.13 |
Ethanolamine Oleate |
|
06.04.01.01 |
Ethinylestradiol |
|
08.03.01 |
Ethinylestradiol |
|
07.03.01 |
Ethinylestradiol / levonorgestrel phased pill TriRegol® |
For existing patients only. No longer routinely recommended |
07.03.01 |
Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20® |
|
07.03.01 |
Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel 20/150® |
|
07.03.01 |
Ethinylestradiol 30 mcg / drospirenone 3 mg Lucette®/Yasmin ® |
Use for acne is off label
|
07.03.01 |
Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel 30/150® |
|
07.03.01 |
Ethinylestradiol 30mcg / gestodene 75 mcg Millinette® |
|
07.03.01 |
Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30® |
Rigevidon brand is 
Microgynon brand is  |
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin® |
|
07.03.01 |
Ethinylestradiol 35 mcg / noresthisterone 500mcg Ovysmen® |
|
07.03.01 |
Ethinylestradiol 35 mcg/norgestimate 250mcg Cilique ® |
|
07.03.01 |
Ethinylestradiol with etonogestrel NuvaRing® |
Low strength. |
07.03.01 |
Ethinylestradiol/norelgestromin Evra® |
|
04.08.01 |
Ethosuximide |
|
15.02 |
Ethyl Chloride Cryogesic® |
|
15.01.01 |
Etomidate Hypnomidate® |
|
07.03.02.02 |
Etonorgestrel Nexplanon® |
Only to be inserted and removed by trained professionals |
08.01.04 |
Etoposide |
|
10.01.01 |
Etoricoxib Arcoxia® |
|
05.03.01 |
Etravirine |
|
08.01.05 |
Everolimus Votubia® |
For use as per commissioning criteria set by NHS England |
08.01.05 |
Everolimus Afinitor® |
|
02.11 |
Evicel® kit |
Specialist use only
|
02.12 |
Evolocumab Repatha® |
|
13.02.01 |
ExCetra® |
Similar to Cetraben cream
|
08.03.04.01 |
Exemestane |
|
06.01.02.03 |
Exenatide Byetta® |
|
06.01.02.03 |
Exenatide prolonged release Bydureon® |
Once weekly formulation. |
02.12 |
Ezetimibe Ezetrol® |
Mainly reserved as an adjunct to statins for patients with primary hypercholesterolaemia. |
01.03.01 |
Famotidine |
For use only as an alternative H2-antagonist when ranitidine is not available, and a proton pump inhibitor is not suitable.
|
10.01.04 |
Febuxostat Adenuric® |
|
02.12 |
Fenofibrate |
First choice fibrate.
Consider only when a statin or other treatments are contraindicated or not tolerated. |
04.07.02 |
Fentanyl Actiq® |
Adult Acute Pain Team only
For painful procedures
Fentanyl lozenge with oromucosal applicator |
04.07.02 |
Fentanyl |
Not first line opioid choice |
04.07.02 |
Fentanyl PecFent® |
For cancer care/palliative care specialist initiation only.
Prescribe by brand name.
For the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Only for patients unable to tolerate, or unsuitable for treatment with, oral formulations of other opioids (e.g. morphine, oxycodone).
|
04.07.02 |
Fentanyl Abstral® |
For cancer care/palliative care specialist initiation only.
Prescribe by brand name.
For the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Only for patients unable to tolerate, or unsuitable for treatment with, oral formulations of other opioids (e.g. morphine, oxycodone). |
15.01.04.03 |
Fentanyl |
|
09.01.01.02 |
Ferric Carboxymaltose Ferinject® |
Drug of choice in antenatal and postnatal women. See local Trust Guideline. |
09.01.01.02 |
Ferric Derisomaltose Monofer® |
previously known as 'iron isomaltoside'. Name changed in Sept 2020 |
09.01.01.01 |
Ferric maltol Feraccru® |
Gastroenterology specialist initiation only.
Only for patients with IBD unable to tolerate other iron preparations
Each capsule contains 30mg elemental iron |
09.01.01.01 |
Ferrous fumarate |
|
09.01.01.01 |
Ferrous fumarate and folic acid Pregaday® |
Each tablet contains ferrous fumarate 322mg (equivalent to 100mg elemental iron) and folic acid 0.35mg
Licensed for use in second and third trimester of pregnancy for prophylaxis against iron deficiency and megaloblastic anaemia of pregnancy |
09.01.01.01 |
Ferrous sulfate |
Each tablet contains ferrous sulfate 200mg equivalent to 65mg elemantal iron |
03.04.01 |
Fexofenadine |
|
20 |
Fibrin Sealant Tisseel® |
|
05.01.07 |
Fidaxomicin |
Microbiology recommendation only for first episode of severe Clostridium difficile when concurrent antibiotics cannot be stopped and for second episodes of Clostridium difficile.
|
10.01.03 |
Filgotinib Jyseleca® |
|
09.01.06 |
Filgrastim |
Specify brand |
06.04.02 |
Finasteride |
for men with a significantly enlarged prostate |
08.02.04 |
Fingolimod |
|
02.03.02 |
Flecainide |
Specialist use only.
|
02.03.02 |
Flecainide |
Specialist use only
Unlicensed liquid special 25mg in 5mL restricted to paediatrics unable to swallow until solid dosage forms are suitable.
|
13.10.05 |
Flexible collodion BP |
|
05.01.01.02 |
Flucloxacillin |
|
05.02.01 |
Fluconazole |
|
05.02.01 |
Fluconazole |
|
05.02.05 |
Flucytosine |
|
08.01.03 |
Fludarabine Phosphate |
|
06.03.01 |
Fludrocortisone |
|
13.04 |
Fludroxycortide |
Prescribe as generic - Haelan brand discontinued Sept 2016
|
15.01.07 |
Flumazenil |
|
12.01.01 |
Flumetasone 0.02% with clioquinol 1% Locorten Vioform ® |
|
11.04.01 |
Fluocinolone acetonide Iluvien® |
|
11.08.02 |
Fluorescein |
Minims®. Preservative-free. |
11.04.01 |
Fluorometholone FML liquifilm ® |
|
08.01.03 |
Fluorouracil |
|
13.08.01 |
Fluorouracil 5% Efudix® |
Treatment of choice for actinic keratoses - recommended by Community Dermatology services (see guidance here). |
13.08.01 |
Fluorouracil and salicylic acid Actikerall® |
|
04.03.03 |
Fluoxetine |
consider oral solution as a more cost effective alternative to 10mg capsules
|
04.02.01 |
Flupentixol |
|
04.03.04 |
Flupentixol |
|
04.02.02 |
Flupentixol decanoate |
For deep intramuscular injection
|
08.03.04.02 |
Flutamide |
|
03.02 |
Fluticasone /umeclidinium / vilanterol Trelegy Ellipta® |
Prescribing by brand name recommended
For COPD use only |
12.02.01 |
Fluticasone furoate Avamys® |
Second or third line for nasal allergy for patients who do not respond to beclometasone dipropionate, or who need a different device. |
03.02 |
Fluticasone furoate and vilanterol Relvar Ellipta® |
Prescribing by brand name recommended
Higher strength formulation (184/22) licensed only for asthma, not for COPD |
03.02 |
Fluticasone propionate |
Prescribing by brand name recommended
|
12.02.01 |
Fluticasone propionate Flixonase Nasule Drops® |
For treatment of symptoms of severe chronic rhinosinusitis with nasal polyps as second line option if control with glucocorticoid nasal sprays is insufficient.
unlicensed in children under 16 years old.
|
13.04 |
Fluticasone propionate 0.005% Cutivate® |
|
13.04 |
Fluticasone propionate 0.05% Cutivate® |
|
03.02 |
Fluticasone propionate and formoterol Flutiform® |
Prescribing by brand name recommended
Licensed for asthma only, not for COPD |
09.01.02 |
Folic Acid |
|
06.05.01 |
Follitropin Alfa |
|
18 |
Fomepizole |
unlicensed
|
02.08.01 |
Fondaparinux Arixtra® |
- for thromboprophylaxis when history of heparin-induced thrombocytopenia only when danaparoid is unobtainable
- as an adjunct to thrombolysis with tenecteplase in STEMI
- for NSTEMI
- for superficial thrombophlebitis
|
13.07 |
Formaldehyde 0.75% Veracur® |
|
03.01.01.01 |
Formoterol fumarate |
Prescribe by brand name
e.g. Atimos Modulite; Formoterol Easyhaler; Oxis Turbohaler |
A2.02.02.03 |
Forticreme ® Complete |
4 x 125g in stock in pharmacy.
Vanilla/chocolate/forest fruit |
A2.02.01.02 |
Fortijuce ® |
24 x 200ml stocked in pharmacy
Apple/Lemon/Strawberry
Orange/Forest Fruit/Blackcurrant - Not held in stock but available to order through pharmacy |
A2.02.02.02 |
Fortimel ® Regular |
Not held in stock but available to order through pharmacy
200ml - Forest Fruit/Vanilla/Chocolate/Strawberry |
A2.01.03.03 |
Fortini® |
24 x 200ml stocked in pharmacy.
Strawberry/Vanilla
For paediatric wards only |
A2.02.02.03 |
Fortini® compact multifibre |
Not held in stock but available to order through pharmacy
4x125ml - Strawberry/Neutral |
A2.03 |
Fortini® creamy fruit multifibre |
Not held in stock but available to order through pharmacy
4 x 100g - Berry, Summer fruit
Paediatric wards only |
A2.02.01.02 |
Fortini® smoothie multifibre |
200ml stocked in pharmacy.
Summer fruit/berry fruit
Paediatric wards only |
A2.02.02.03 |
Fortisip ® Compact Fibre |
Not held in stock but available to order through pharmacy.
125ml - Vanilla/Strawberry/Mocha |
A2.02.02.03 |
Fortisip ® Extra |
Not held in stock but available to order through pharmacy
200ml - Chocolate/Forest Fruit/Vanilla/Strawberry |
A2.02.02.01 |
Fortisip ® Bottle |
Chocolate, strawberry, vanilla, banana stocked in pharmacy |
A2.02.02.01 |
Fortisip ® Multi Fibre |
Not held in stock but available to order through pharmacy
200ml - Chocolate/Orange/Vanilla |
A2.02.02.03 |
Fortisip® Compact |
24 x 125ml in stock in pharmacy. Banana, vanilla, strawberry, mocha |
A2.02.02.03 |
Fortisip® Compact Protein |
Not held in stock but available to order through pharmacy
Vanilla/Strawberry/banana/Mocha |
A2.02.02.01 |
Fortisip® Yoghurt style |
Not held in stock but available to order through pharmacy
24 x 200ml - Vanilla/Lemon/Raspberry |
05.03.01 |
Fosamprenavir |
|
05.03.02.02 |
Foscarnet Sodium |
|
05.01.07 |
Fosfomycin |
Prescribe as Monuril sachets in primary care |
04.07.04.02 |
Fremanezumab Ajovy® |
Note: not supported for use in episodic migraine (see NICE TA631).
|
A2.02.02.01 |
Fresubin thickened stage 2® |
4 x 200ml stocked in pharmacy.
Vanilla/Wild strawberry |
13.05.02 |
Fumaric acid esters Fumaderm® |
Dermatology only; for psoriasis
Unlicensed
|
02.02.02 |
Furosemide |
|
11.03.01 |
Fusidic acid |
|
13.10.01.02 |
Fusidic acid 2% |
|
A2.07 |
GA1 Anamix ® Infant |
Ordered via main stores |
04.07.03 |
Gabapentin |
For neuropathic pain in accordance with NICE Guidelines
First line if pain is lancinating in nature (‘electric shocks’) |
04.08.01 |
Gabapentin |
|
04.11 |
Galantamine |
Liquid only for patients unable to swallow tablets |
04.07.04.02 |
Galcanezumab Emgality® |
|
05.03.02.02 |
Ganciclovir |
|
11.03.03 |
Ganciclovir |
for use when aciclovir is not available
|
01.06.07 |
Gastrografin |
Specialist use only
|
01.01.02 |
Gaviscon Advance/Acidex Advance® |
Acidex Advance brand first line choice in primary care (prescribe by brand name).
|
01.01.02 |
Gavison original/Acidex/Peptac® |
Peptac brand first line choice in primary care (prescribe by brand name).
|
08.01.05 |
Gefitinib |
|
09.02.02.02 |
Gelofusine |
|
08.01.03 |
Gemcitabine |
|
08.01.05 |
Gemtuzumab ozogamicin Mylotarg® |
|
05.01.04 |
Gentamicin |
|
11.03.01 |
Gentamicin |
|
12.01.01 |
Gentamicin 0.3% |
|
12.01.01 |
Gentamicin 0.3% with hydrocortisone acetate 1% Gentisone® HC |
|
08.01.05 |
Gilteritinib Xospata® |
|
12.03.05 |
Glandosane ® |
|
08.02.04 |
Glatiramer acetate |
Specialist use only for multiple sclerosis
|
05.03.03.02 |
Glecaprevir with pibrentasvir Maviret® |
|
06.01.02.01 |
Gliclazide |
|
06.01.02.01 |
Glipizide |
|
06.01.04 |
Glucagon injection |
|
06.01.06 |
Glucose Diastix® |
|
06.01.04 |
Glucose 40% |
|
06.01.04 |
Glucose 50% injection |
Use in prolotherapy in the management of SI joint pain is not supported for routine commissioning. Individual patients may be considered via IFR application.
|
09.02.02.01 |
Glucose Intravenous |
Glucose 5% intravenous infusion
Glucose 10% intravenous infusion
Glucose 20% intravenous infusion
Glucose 50% intravenous infusion |
12.03.04 |
Glycerin and lemon mouth swabs |
|
01.06.02 |
Glycerol |
|
11.99.99.99 |
Glycerol (glycerin) BP |
|
02.06.01 |
Glyceryl Trinitrate |
|
02.06.01 |
Glyceryl Trinitrate |
|
01.07.04 |
Glyceryl trinitrate 0.4% |
|
02.06.01 |
Glyceryl Trinitrate 5mg/ml |
|
07.04.04 |
Glycine |
|
03.01.02 |
Glycopyrronium Seebri Breezhaler® |
Prescribing by brand name recommended
Licensed for COPD only, not for asthma |
15.01.03 |
Glycopyrronium |
|
13.12 |
Glycopyrronium (glycopyrrolate) 0.05% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
Dermatology only - for use in iontophoresis, second-line to tap water. To be initiated in secondary care.
|
13.12 |
Glycopyrronium (glycopyrrolate) 2% Formula A |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
Dermatology only.
|
03.01.04 |
Glycopyrronium and indacaterol Ultibro Breezhaler® |
Prescribing by brand name recommended
|
15.01.06 |
Glycopyrronium and Neostigmine |
|
01.02 |
Glycopyrronium Bromide 1mg/5ml |
For severe sialorrhoea in children and adolescents with chronic neurological disorders.
Note: not licensed in adults.
|
01.05.03 |
Golimumab Simponi®) (Gastroenterology |
unlicensed use in Crohns disease (off licence indication).
|
10.01.03 |
Golimumab Simponi®) (Rheumatology |
|
06.05.01 |
Gonadorelin (LHRH) |
|
06.07.02 |
Goserelin |
Red formulary status for fertility treatment. Specialist prescribing only.
|
08.03.04.02 |
Goserelin |
|
04.06 |
Granisetron |
After ondansetron has failed in children receiving chemotherapy and patients with gastrointestinal failure |
04.06 |
Granisetron Sancuso® |
Specialist use only as per licensed indications
|
03.04.02 |
Grass and Tree Pollen Extract Pollinex® |
Specialist allergy clinics only
|
03.04.02 |
Grass pollen allergen extract Grazax® |
Specialist allergy clinics only.
|
02.05.03 |
Guanethidine Monosulphate Ismelin® |
|
04.04 |
Guanfacine Intuniv® |
Specialist initiation only
In accordance with Shared Care Guidelines |
13.05.03 |
Guselkumab |
|
09.08.02 |
Haem Arginate |
|
14.04 |
Haemophilus influenzae type B and Meningococcal group C conjugate vaccine Menitorix® |
|
03.01.05 |
Haleraid ® |
|
04.02.01 |
Haloperidol |
|
04.09.03 |
Haloperidol |
|
04.02.02 |
Haloperidol decanoate HALDOL® Decanoate |
For deep intramuscular injection
|
A2.07 |
HCU Anamix ® Infant |
Ordered via main stores |
09.02.02 |
Heparin |
|
02.08.01 |
Heparin calcium |
|
02.08.01 |
Heparin sodium |
|
02.08.01 |
Heparin sodium |
Restricted use in primary care. GPs to prescribe only for children for administration by specialist paediatric community nurses.
|
14.04 |
Hepatitis A vaccine |
|
14.04 |
Hepatitis A vaccine with typhoid vaccine Hepatyrix® |
|
14.05.02 |
Hepatitis B immunoglobulin HBIG |
Microbiology request only |
14.04 |
Hepatitis B vaccine |
|
07.04.04 |
Hexaminolevulinate |
Urology specialist only
|
09.02.01.02 |
High sodium powders |
Nutrition team only. Patients may prepare themselves following advice and recipe from specialist/nutrition team.
Unlicensed
|
09.02.02.01 |
Histidine, tryptophan, ketoglutarate Custodiol® HTK |
Restricted - for specialist cardiac surgery use only. For administration into renal arteries as renal protection during open thoracoabdominal aortic aneurysm repair surgery.
use for this indication is off label
Classed as a Medical device - CE Marked |
09.02.02.02 |
Human albumin |
Human albumin 4.5% solution
Human albumin 20% solution |
06.05.01 |
Human Menopausal Gonadotrophins Menopur/Merional® |
|
14.04 |
Human papilloma virus vaccine Gardasil® |
|
07.05 |
Hyaluronic acid |
For localised use in the uterus only, for prevention of adhesions. Use products registered as medical devices (i.e. CE marked) or medicines only, e.g. Hyalobarrier®; Hyaregen®; Materegen®.
|
02.05.01 |
Hydralazine |
|
02.05.01 |
Hydralazine |
|
01.05.02 |
Hydrocortisone |
|
06.03.01 |
Hydrocortisone |
Modified-release tablets (Plenadren) are non-formulary |
06.03.01 |
Hydrocortisone Alkindi® |
Restricted for use only when standard tablets are not suitable or practical, e.g. infants/young children on doses <5mg.
UHS will only routinely stock lower strengths, i.e. 0.5mg, 1mg and 2mg.
Patients on doses ≥5mg should be switched to standard tablets, which can be divided using a tablet cutter.
Unlicensed in patients ≥18 years. Discuss options for adult patients unable to swallow tablets with pharmacist. |
13.04 |
Hydrocortisone 0.5% & 1% |
|
13.04 |
Hydrocortisone 1% with clotrimazole 1% Canesten HC® |
For short-term use
|
13.04 |
Hydrocortisone 1% with fusidic acid 2% Fucidin H® |
For short-term use
|
13.04 |
Hydrocortisone 1% with miconazole 2% Daktacort® |
For short-term use
|
12.03.01 |
Hydrocortisone 2.5mg |
Available OTC
|
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
|
13.04 |
Hydrocortisone butyrate 0.1% Locoid® |
|
11.04.01 |
Hydrocortisone sodium phosphate Softacort® |
An alternative option to prednisolone preservative-free eye drops. |
12.01.01 |
Hydrocortisone/neomycin/polymixin B Otosporin® |
|
13.11.06 |
Hydrogen peroxide 10 Vol (3%) |
|
13.11.06 |
Hydrogen peroxide BP |
10 Vol (3%)
20 Vol (6%) |
A2.03.01 |
Hydrolysed Nutriprem (Cow and Gate®) |
Ordered through main stores |
13.08.02 |
Hydroquinone 5%, hydrocortisone 1% and tretinoin 0.1% Pigmanorm® |
Unlicensed
Dermatology only.
|
09.01.02 |
Hydroxocobalamin Vitamin B12 |
IM injection preferred over oral administration for non-dietary vitamin B12 deficiency |
18 |
Hydroxocobalamin Cyanokit® |
|
18 |
Hydroxocobalamin |
|
08.01.05 |
Hydroxycarbamide |
|
10.01.03 |
Hydroxychloroquine |
Supported only for indications detailed in Shared Care Guidelines.
Not for use in Covid-19 treatment/prevention outside of clinical trials (see links below). Seek further advice from infection control specialist/pharmacy team. |
13.05.03 |
Hydroxychloroquine dermatology |
Supported only for use in indications detailed in Shared Care guidelines.
Not for use in Covid-19 treatment/prevention outside of clinical trials (see links below). Seek further advice from infection control specialist/pharmacy team. |
11.99.99.99 |
Hydroxypropylmethylcellulose in balanced salt solution inj |
Unlicensed
|
03.04.01 |
Hydroxyzine |
Dermatology only
|
11.08.01 |
Hylo Night ® |
For use in line with DPC dry eye guidelines (link below)
Preservative-free
Contains retinol palmitate (vitamin A), liquid paraffin and wool fat.
Previously known as VitA-POS eye ointment. |
01.02 |
Hyoscine Butylbromide |
|
04.06 |
Hyoscine hydrobromide |
Tablets/patch may also be used off-label for hypersalivation |
15.01.03 |
Hyoscine Hydrobromide |
|
11.08.01 |
Hypromellose |
To be used in line with DPC dry eye guidelines (link below).
Only for patients allergic/intolerant of preservatives or high risk of developing allergy.
May be prescribed as unit dose (single use) eye drops or multi-dose bottle (various brands available - refer to Drug Tariff Part IXA for current prices in primary care). |
11.08.01 |
Hypromellose |
To be used in line with DPC dry eye guidelines (link below)
|
06.06.02 |
Ibandronic acid |
For prevention of skeletal events in patients with breast cancer and bone metastases.
'Off label' use for post-menopausal women with breast cancer who are assessed by a specialist to be at sufficient risk of breast cancer recurrence. Refer to DPC shared care guidance: Adjuvant Bisphosphonates for Early Breast Cancer Feb 2018
|
06.06.02 |
Ibandronic acid |
Specialist use only for osteoporosis.
For patients unable to tolerate oral medication |
06.06.02 |
Ibandronic acid |
For osteoporosis |
08.01.05 |
Ibrutinib Imbruvica® |
|
07.01.01.01 |
Ibuprofen injection |
|
10.01.01 |
Ibuprofen |
A first line NSAID, except for gout |
10.01.01 |
Ibuprofen |
|
10.03.02 |
Ibuprofen 5% |
Self Care Medicine
|
03.04.03 |
Icatibant Firazyr® |
For use as per commissioning criteria set by NHS England
|
13.05.01 |
Ichthammol 1% & zinc oxide 15% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05.01 |
Ichthammol glycerin BPC |
|
08.01.02 |
Idarubicin |
|
02.08.03 |
Idarucizumab Praxbind® |
On Consultant Haematologist advice only (refer to UHS guideline).
- When rapid reversal of dabigatran is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
|
11.08 |
Idebenone Raxone® |
In line with NHS England commissioning criteria
|
08.01.05 |
Idelalisib |
|
08.01.01 |
Ifosfamide |
|
02.05.01 |
Iloprost 100micrograms/ml |
Refer to UHS Iloprost Intravenous Infusion Guidelines |
08.01.05 |
Imatinib |
|
05.01.02.02 |
Imipenem with Cilastatin |
|
04.03.01 |
Imipramine |
May be considered as a potential second line alternative when amitriptyline is not suitable/not tolerated
|
13.07 |
Imiquimod 5% |
For anogenital warts.
Not supported for treatment of actinic keratoses.
|
03.01.01.01 |
Indacaterol Onbrez Breezhaler® |
Prescribe by brand name.
Licensed only for COPD, not for asthma |
02.02.01 |
Indapamide |
|
11.08.02 |
Indocyanine green |
|
07.01.01.01 |
Indometacin |
Unlicensed
|
10.01.01 |
Indometacin |
Not a first line NSAID
Liquid is unlicensed
|
13.11.01 |
Industrial Methylated Spirit 70%/95% IMS |
|
01.01.02 |
Infant Gaviscon ® |
Children only |
A2.01.03.02 |
Infatrini ® |
Not held in stock but available to order through pharmacy
100ml/200ml/500ml - Unflavoured |
A2.03.01 |
Infatrini Peptisorb® |
200ml stocked in pharmacy |
01.05.03 |
Infliximab Remicade®)(Gastroenterology |
Specify brand
|
01.05.03 |
Infliximab biosimilar Remsima®, Inflectra®, Flixabi®) (Gastroenterology |
Specify brand.
Flixabi brand is black triangle.
Subcutaneous Remsima® prefilled syringes/ pens can be used as an alternative to IV for use in rheumatology or gastroenterology indications. |
10.01.03 |
Infliximab/infliximab biosimilar rheumatology |
Specify brand (e.g. Remicade®, Remsima®, Inflectra®, Flixabi® , Zessly® )
Subcutaneous Remsima® prefilled syringes/ pens can be used as an alternative to IV for use in rheumatology or gastroenterology indications.
|
13.05.03 |
Infliximab/infliximab biosimilar dermatology |
Specify brand (e.g. Remicade®, Remsima®, Inflectra®, Flixabi® , Zessly® )
|
14.04 |
Influenza vaccine |
|
09.08.01 |
Inotersen Tegsedi® |
|
08.01.05 |
Inotuzumab ozogamicin Besponsa® |
|
06.01.01.01 |
Insulin Humulin® S |
|
06.01.01.01 |
Insulin Actrapid® |
|
06.01.01.01 |
Insulin 500 units in 1mL Humulin R® |
Unlicensed.
Monitoring and prescribing by specialists only.
|
06.01.01.01 |
Insulin Aspart NovoRapid® |
|
06.01.01.01 |
Insulin aspart fast-acting Fiasp® |
Specialist recommendation, only for type 1 diabetes
|
06.01.01.02 |
Insulin degludec Tresiba® |
As per DPC Jun 19 |
06.01.01.02 |
Insulin degludec Tresiba® |
Initiated and stabilised by a specialist for difficult to manage patients with type 1 diabetes
|
06.01.01.02 |
Insulin degludec and liraglutide Xultophy® |
|
06.01.01.02 |
Insulin detemir Levemir® |
|
06.01.01.02 |
Insulin glargine Lantus® |
Specify brand.
Biosimilar preferred for new patients. |
06.01.01.02 |
Insulin glargine Toujeo® |
Specialist initiation
|
06.01.01.02 |
Insulin glargine biosimilar Abasaglar®; Semglee® |
Specify brand.
|
06.01.01.01 |
Insulin lispro Humalog® |
Specialist initiation
|
06.01.01.01 |
Insulin lispro Humalog® |
|
05.03.03 |
Interferon alfa |
|
08.02.04 |
Interferon Alfa |
|
08.02.04 |
Interferon Beta |
For use as per specialist commissioning criteria
Not for use in Covid-19 treatment outside of clinical trials. Seek further advice from infection control specialist/pharmacy team.
|
07.03.02.03 |
Intra-uterine Progestogen Only System Mirena® |
Contains 52mg levonorgestrel |
07.03.02.03 |
Intra-uterine Progestogen Only System Kyleena® |
For contraception only
Contains 19.5mg levonorgestrel |
07.03.02.03 |
Intra-uterine Progestogen Only System Levosert® |
Alternative to Mirena (for contraception and heavy menstrual bleeding only - not licensed for endometrial protection with HRT)
Note: different insertion device/technique vs Mirena
Contains 52mg levonorgestrel |
07.03.02.03 |
Intra-uterine Progestogen Only System Kyleena® |
Off-label use in obstetrics for heavy menstrual bleeding where Mirina or Levosert devices are too large.
Contains 19.5mg levonorgestrel |
13.11.04 |
Iodine alcoholic solution BP |
|
06.02.02 |
Iodine and Iodide |
|
13.11.04 |
Iodine aqueous solution BP |
|
08.01.05 |
Ipilimumab |
|
03.01.02 |
Ipratropium |
|
08.01.05 |
Irinotecan |
|
09.01.01.02 |
Iron Sucrose Venofer® |
|
08.01.05 |
Isatuximab Sarclisa® |
|
05.02.01 |
Isavuconazole Cresemba® |
|
15.01.02 |
Isoflurane |
|
13.02.01 |
Isomol®/Zerodouble® |
Also suitable for use as a soap substitute.
Similar to Doublebase gel. |
05.01.09 |
Isoniazid |
Liquid is unlicensed
|
06.01.01.02 |
Isophane Insulin Insulatard® |
|
06.01.01.02 |
Isophane Insulin Humulin® I |
|
02.07.01 |
Isoprenaline |
unlicensed
|
13.11.01 |
Isopropyl alcohol 70% |
|
02.06.01 |
Isosorbide Mononitrate Isotard XL® |
|
02.06.01 |
Isosorbide Mononitrate |
|
13.06.02 |
Isotretinoin |
Hospital only
|
01.06.01 |
Ispaghula Husk |
|
05.02.01 |
Itraconazole |
|
05.02.01 |
Itraconazole |
|
A2.07 |
IVA Anamix ® Infant |
Ordered via main stores |
02.06.03 |
Ivabradine |
Third-line option for stable angina in accordance with NICE guidelines |
02.06.03 |
Ivabradine |
For heart failure |
03.07 |
Ivacaftor Kalydeco® |
Restricted to patients as per NHS England commissioning policies
SSC2227 New expanded access to 'off label' use (FEB 2021)
With imediate effect, NHSE has agreed patients with F508DEL mutation plus any other mutation, for whom there aren't currently any suitable licensed medicines that meet their needs may be considered by their CF clinician for 'off label' use of Kaftrio |
13.06.01 |
Ivermectin |
First line option for papulopustular rosacea
|
13.10.04 |
Ivermectin |
On microbiology advice only
Unlicensed
|
08.01.05 |
Ixazomib Ninlaro® |
|
10.01.03 |
Ixekizumab Taltz® |
|
13.05.03 |
Ixekizumab Taltz® |
|
15.01.01 |
Ketamine |
|
15.01.01 |
Ketamine High strength 100mg/ml |
unlicensed
Consultant anaesthetist use only. For acutely agitated/confused patients only
|
15.01.01 |
Ketamine S (preservative free) |
unlicensed
Child Health only |
A2.03.02 |
KetoCal ® 4:1 LQ |
Ordered via main stores |
05.02.02 |
Ketoconazole |
Specialist use only
unlicensed
MHRA - Oral ketoconazole: do not prescribe or use for fungal infections—risk of liver injury outweighs benefits |
13.09 |
Ketoconazole 2% |
|
13.10.02 |
Ketoconazole 2% |
|
11.08.02 |
Ketorolac trometamol Acular® |
Note: licensed for use up to 3 weeks post-operatively
|
15.01.04.02 |
Ketorolac trometamol |
|
01.06.05 |
Klean-Prep ® |
|
02.04 |
Labetalol |
|
02.04 |
Labetalol |
|
04.08.01 |
Lacosamide Vimpat ® |
For refractory partial epilepsy
Tablet/liquid
Injection is red on formulary for those NBM
|
11.08.01 |
Lacri-lube®/Refresh Night Time®/Xailin Night® |
To be used in line with DPC dry eye guidelines (link below)
Contains white soft paraffin, liquid paraffin, wool alcohols. |
01.05 |
Lactobacillus |
For use on prescription under microbiology recommendation only
|
01.06.04 |
Lactulose |
|
03.04.02 |
Lais® 1,000 AU |
Unlicensed
Specialist allergy clinics only. For use only when licensed alternatives are not suitable.
|
05.03.01 |
Lamivudine |
|
05.03.01 |
Lamivudine/abacavir/dolutegravir Triumeq® |
|
04.08.01 |
Lamotrigine |
For primary generalised epilepsy (including absences and myoclonus), partial seizures, secondary generalised tonic-clonic seizures. |
03.04.03 |
Lanadelumab 300mg Takhzyro® |
|
08.03.04.03 |
Lanreotide Somatuline Autogel® |
For self administration
Shared Care Guideline for Lanreotide & Octreotide Long Acting Injection in Acromegaly (GP Summary) can be found here |
01.03.05 |
Lansoprazole |
Orodispersible tablets to be used only for enteral tubes/patients with swallowing difficulties
|
09.08.01 |
L-Arginine |
Unlicensed
|
08.01.05 |
Larotrectinib Vitrakvi® |
|
11.06 |
Latanoprost |
Generic prescribing recommended.
First line prostaglandin analogue.
Unit dose drops only for patients allergic/intolerant of preservatives, or high risk of developing allergy
|
11.06 |
Latanoprost with timolol |
Generic prescribing recommended
First choice if a combination prostaglandin analogue/beta-blocker is required.
Unit dose drops only for patients allergic/intolerant of preservatives, or high risk of developing allergy
|
13.02.02 |
LBF® Sterile Barrier Film |
Refer to Wound Formulary for further details |
05.03.03.02 |
Ledipasvir with sofosbuvir Harvoni® |
|
10.01.03 |
Leflunomide |
|
08.02.04 |
Lenalidomide Revlimid® |
|
08.01.05 |
Lenvatinib Kisplyx®; Lenvima® |
Lenvima for thyroid and hepatocellular carcinoma, Kisplyx for renal cell carcinoma
|
05.03.02.02 |
Letermovir Prevymis® |
|
08.03.04.01 |
Letrozole |
|
06.07.02 |
Leuprorelin |
Red formulary status for fertility treatment (off label use). Specialist prescribing only.
|
08.03.04.02 |
Leuprorelin acetate |
|
04.08.01 |
Levetiracetam |
|
04.08.01 |
Levetiracetam |
|
11.06 |
Levobunolol |
Not a first line choice.
Unit dose drops only for patients allergic/intolerant of preservative, or high risk of developing allergy
|
15.02 |
Levobupivacaine Chirocaine® |
High risk blocks only e.g. interscalene
Supply only to be made by Critical Care Pharmacists and use carefully monitored |
15.02 |
Levobupivacaine |
|
09.08.01 |
Levocarnitine |
|
05.01.12 |
Levofloxacin Quinsair® |
For use only in accordance with Aug 2018 NHS England Clinical Commissioning Policy for chronic Pseudomonas lung infection in cystic fibrosis (adults)
|
05.01.12 |
Levofloxacin |
Tablets/injection red for prophylaxis in multiple myeloma in line with UHS guidance (12 weeks treatment). Haematology only.
Tablets green for H pylori eradication in line with SCAN community antibiotic guidelines (note: not a first-line option)
|
11.03.01 |
Levofloxacin |
Following corneal graft surgery.
Unit dose drops/preservative free preparation if installation ≥ 6 times daily
|
04.02.01 |
Levomepromazine |
|
04.06 |
Levomepromazine |
Palliative care |
07.03.05 |
Levonorgestrel Levonelle® 1500 |
|
07.03.02.01 |
Levonorgestrel 30 microgram Norgeston® |
For existing patients |
02.01.02 |
Levosimendan |
Unlicensed
Specialist use only in cardiac surgery patients for:
- Life threatening post-operative low cardiac output syndrome where the patient is on maximum therapy (catecholamines) and phosphodiesterase inhibitors are contra-indicated/not tolerated.
- Rarely pre-operatively for patients with very low cardiac output/ejection fraction (e.g. LVEF <25%).
|
06.02.01 |
Levothyroxine |
|
02.03.02 |
Lidocaine |
|
04.07.03 |
Lidocaine |
Restricted use.
for use in patients who have been treated in line with NICE CG173: Neuropathic pain, but are still experiencing pain associated with previous herpes zoster infection (post-herpetic neuralgia) (licensed indication).
Amber for chronic neuropathic pain/focal neuralgia [ 'off label' use] in exceptional circumstances only (e.g. other treatment options have failed or cannot be used due to co-morbidities) in a co-operation arrangement with chronic pain or cancer care/palliative care specialist teams as per DPC Chronic Pain Prescribing Guidelines or Wessex Palliative Care Guidelines.
for use in rib fracture pain (see section 15.02)
|
15.02 |
Lidocaine |
0.5%, 1% and 2% |
15.02 |
Lidocaine |
|
15.02 |
Lidocaine |
|
15.02 |
Lidocaine |
‘Off label’ short term use (usual max 2 weeks) at UHS for management of acute pain associated with traumatic rib fractures (refer to protocol). All patients prescribed lidocaine plasters for rib fracture pain should be referred to the acute pain team.
Not suitable for primary care prescribing for this indication. For use in neuropathic pain refer to section 04.07.03. |
15.02 |
Lidocaine 0.4% and glucose 5% |
|
02.03.02 |
Lidocaine 0.4% in glucose 5% |
|
15.02 |
Lidocaine 2.5% with Prilocaine 2.5% EMLA® |
|
01.07.04 |
Lidocaine 5% |
|
15.02 |
Lidocaine and chlorhexidine Instillagel® |
|
15.02 |
Lidocaine with Adrenaline Lignospan® |
Lidocaine 1% and adrenaline 1:80,000
Lidocaine 2% and adrenaline 1:80,000
Lidocaine 2% and adrenaline 1:200,000 |
15.02 |
Lidocaine, adrenaline and tetracaine LAT |
Unlicensed, ED for children only
|
01.06.07 |
Linaclotide Constella® |
According to local algorithm |
06.01.02.03 |
Linagliptin |
For patients with renal impairment |
05.01.07 |
Linezolid |
Specialist use only. Only to be used in primary care under microbiologist recommendation. Specialist to advise of any monitoring or potential drug interactions.
Liquid for patients unable to swallow tabs. |
06.02.01 |
Liothyronine |
|
06.02.01 |
Liothyronine |
for use in thyroid cancer, radioiodine ablation, iodine scanning or stimulated thyroglobulin test.
for thyroid deficiency. Specialist initiation. Not routinely commissioned in Hampshire - IFR application required. Ongoing prescribing in primary care in exceptional circumstances only (refer to SHIP Priorities Committee statement, DPC Shared Care guidance, and Liothyronine prior approval form)
|
08.01.05 |
Liposomal daunorubicin-cytarabine Vyxeos® |
|
13.02.01 |
Liquid paraffin, white soft paraffin 50/50 |
Preservative and fragrance free.
Very greasy. |
A2.04.01.02 |
Liquigen ® |
Ordered via main stores |
06.01.02.03 |
Liraglutide |
(only Victoza® brand): Type 2 diabetes mellitus [monotherapy (if metformin inappropriate) or in combination with other antidiabetic drugs] in adults.
(only Saxenda® brand): Weight management in adults according to NICE TA664 |
04.04 |
Lisdexamfetamine Elvanse® |
For use according to licence. |
02.05.05.01 |
Lisinopril |
|
04.02.03 |
Lithium carbonate |
SPECIFY BRAND
Once stable, patients should be maintained on the same brand.
After negotiating new prices with the Department of Health and Social Care (DHSC), Essential Pharma has agreed to keep supplying the NHS with Priadel, which it previously announced it would be withdrawing from the UK market in April 2021.
|
04.02.03 |
Lithium Citrate |
Not dose-equivalent to MR tablets
SPECIFY BRAND |
A2.03.01 |
Locasol ® |
Ordered via main stores |
11.04.02 |
Lodoxamide Alomide® |
Ophthalmology only
|
04.03.01 |
Lofepramine |
|
02.12 |
Lomitapide Lojuxta®▼ |
In line with commissioning criteria
|
08.01.01 |
Lomustine |
|
01.04.02 |
Loperamide |
|
05.03.01 |
Lopinavir/ritonavir Kaletra® |
For use in licensed indications only.
Not for use in Covid-19 treatment outside of clinical trials. Seek further advice from infection control specialist/pharmacy team. |
03.04.01 |
Loratadine |
|
04.01.02 |
Lorazepam |
|
04.01.02 |
Lorazepam |
|
04.08.02 |
Lorazepam epilepsy |
|
15.01.04.01 |
Lorazepam |
|
08.01.05 |
Lorlatinib Lorviqua® |
|
02.05.05.02 |
Losartan |
|
11.04.01 |
Loteprednol Lotemax® |
Note: use for >2 weeks and for indications other than inflammation following ocular surgery is unlicensed.
|
14.04 |
Low dose diphtheria, tetanus, acellular pertussis and IPV Repevax ® |
|
14.04 |
Low dose diphtheria, tetanus, IPV Revaxis ® |
|
13.02.01 |
Lubricating jelly |
|
03.07 |
Lumacaftor/ivacaftor Orkambi® |
Restricted to patients as per NHS England commissioning policies |
09.01.04 |
Lusutrombopag Mulpleo® |
|
08.01.05 |
Lutetium (177Lu) oxodotreotride |
|
05.01.03 |
Lymecycline |
Dermatology only
|
13.06.02 |
Lymecycline |
|
15.03 |
Lysine/arginine |
For renal protection during IV radionuclide DOTATATE therapy |
02.05.01 |
Macitentan Opsumit ® |
For patients managed under a shared care agreement with the Royal Brompton Hospital only. |
01.06.04 |
Macrogol oral powder |
For chronic constipation/faecal impaction |
01.06.04 |
Macrogol Paediatric oral powder |
|
01.06.05 |
Macrogols Moviprep® |
|
09.05.01.03 |
Magnesium Aspartate Magnaspartate® |
|
09.05.01.03 |
Magnesium Glycerophosphate Neomag® |
|
09.05.01.03 |
Magnesium Glycerophosphate |
unlicensed
|
01.06.04 |
Magnesium Hydroxide Mixture BP |
|
09.05.01.03 |
Magnesium oxide |
Unlicensed
If compliance problems with magnesium glycerophosphate |
09.05.01.03 |
Magnesium sulfate |
50% (5g in 10ml; 1g in 2ml)
20% (10g in 50ml) unlicensed - For use within maternity at Princess Anne hospital
10% (1g in 10ml) |
02.03.02 |
Magnesium sulfate 50% |
|
13.10.05 |
Magnesium sulfate paste BP |
|
01.01.01 |
Magnesium Trisilicate mixture |
|
13.10.04 |
Malathion 0.5% |
For head and pubic lice. Second line option for scabies.
Self Care Medicine. Can be purchased OTC (e.g. Derbac-M®).
|
02.02.05 |
Mannitol |
|
03.07 |
Mannitol inhalation |
In addition to Bronchitol® as per NICE TA 266, Osmohale® is used for diagnostic testing |
05.03.01 |
Maraviroc Celsentri® |
|
A2.03.01 |
MCT Pepdite (Nutricia®) |
Ordered through main stores
400g |
A2.03.01 |
MCT Pepdite 1+ (Nutricia®) |
Ordered through main stores |
14.04 |
Measles, Mumps and Rubella Vaccine, Live (MMR) |
|
05.05.01 |
Mebendazole |
|
01.02 |
Mebeverine |
|
A2.04.01.02 |
Medium-chain Triglyceride (MCT) Oil |
Ordered through main stores
500ml |
06.04.01.02 |
Medroxyprogesterone Acetate |
|
07.03.02.02 |
Medroxyprogesterone acetate Depo-Provera®/ Sayana Press® |
|
08.03.02 |
Medroxyprogesterone acetate |
|
10.01.01 |
Mefenamic Acid |
Not a first line NSAID.
For dysmenorrhoea and menorrhagia only, but no evidence to support superiority vs other NSAIDs, and safety concerns in overdose. Use only if preferred NSAIDs (naproxen or ibuprofen) not suitable. |
05.04.01 |
Mefloquine |
|
08.03.02 |
Megestrol acetate |
|
04.01.01 |
Melatonin Circadin®/ Slenyto® |
CAMHS initiation/supervision only for use in children with sleep disorders in accordance with DPC Shared Care guidance.
Circadin use is off label in children. Slenyto is licensed only for children/adolescents aged 2-18 years with autism spectrum disorder or Smith-Magenis syndrome. Use in all other indications is off label. May be crushed for administration in swallowing difficulties or via feeding tubes if necessary.
Refer to DPC shared care guidance for advice on crushing tablets and flow chart for choice of brand/formulation. |
04.01.01 |
Melatonin Syncrodin® |
CAMHS/sleep specialist initiation/supervision only for use in children with sleep disorders in accordance with DPC Shared Care guidance
Prescribe by brand name (previous names Melatonin PharmaNord/Bio-Melatonin tablets).
Use in children is off label. May be crushed for administration in swallowing difficulties or via feeding tubes if necessary.
Refer to DPC Shared care guidance for instructions on crushing and flow chart for choice of brand/formulation.
Note: Melatonin 3mg tablets (Colonis Pharma) are non-formulary.
|
04.01.01 |
Melatonin 5mg in 5ml Colonis Pharma® |
CAMHS/sleep specialist initiation/supervision only for use in children with sleep disorders in accordance with DPC Shared Care guidance.
Liquid should only be used when tablets (including crushed tablets) are not suitable.
Use in children is off label.
Colonis branded Melatonin liquid contains 150.5mg/1ml of propylene glycol. The EU safety limits for propylene glycol for children under 5 years is 50mg/kg and for those 5 years and over is 500mg/kg. Also contains sorbitol. This brand will not be prescribed or kept in stock at UHS.
Tablets (crushed) or unlicensed liquid specials preferred in infants or children with allergy/intolerant of excipients or in those where the amount of excipient(s) are deemed unsuitable.
Further information on excipients and melatonin can be found here
Refer to DPC Shared Care guidance for flow chart on choice of brand/formulation. |
10.01.01 |
Meloxicam |
Existing patients only.
|
08.01.01 |
Melphalan |
|
08.01.01 |
Melphalan |
|
04.11 |
Memantine |
Southern Health - specialist recommended
Oral solution only for patients unable to swallow tablets.
Oral solution comes in different presentations (e.g. pump, dosing pipette, oral syringe) - offer patient counselling on administration method at point of dispensing
|
09.06.06 |
Menadiol |
|
14.04 |
Meningococcal A, C, W135, and Y conjugate vaccine Menveo® |
|
14.04 |
Meningococcal group B Vaccine Bexsero® |
|
14.04 |
Meningococcal group C conjugate vaccine |
|
13.03 |
Menthol 0.5% in aqueous cream |
Prescribe by brand name in primary care to avoid specials dispensing (e.g. Arjun®, Dermacool®)
|
05.04.04 |
Mepacrine Hydrochloride |
For discoid lupus erythematosus
unlicensed |
15.02 |
Mepivacaine 3% Scandonest Plain® |
For specialist use only in Solent Sexual Health Service.
For selected patients as intra-cervical block to facilitate insertion of intra-uterine contraception (off-label use) in accordance with FSRH guidance.
|
03.04.02 |
Mepolizumab Nucala® |
|
09.08.01 |
Mercaptamine Cystagon® |
In line with NHSE specialist commissioning criteria
|
11.08 |
Mercaptamine (cysteamine) |
Specialist use only in line with NHS England specialist commissioning criteria
Unlicensed
Note: mercaptamine hydrochloride viscous eye drops (Cystadrops) are non-formulary and not routinely commissioned.
|
08.01.03 |
Mercaptopurine |
10mg tablets are unlicensed
|
13.05.03 |
Mercaptopurine dermatology |
10mg tablets unlicensed
|
05.01.02.02 |
Meropenem |
|
05.01.02.02 |
meropenem with vaborbactam Vaborem ® |
Microbiology approval only
|
01.05.01 |
Mesalazine Pentasa® |
Choice of preparation depends on disease location |
01.05.01 |
Mesalazine Salofalk® |
Choice of preparation depends on disease location
Pentasa® granules may be prescribed for those who are already established on this brand (to prevent de-stabilising if switched to Salofalk)
Salofalk® brand to remain first-line preference for new patients.
|
01.05.01 |
Mesalazine Octasa® |
Choice of preparation depends on disease location |
08.01 |
Mesna |
For urothelial toxicity |
13.02.02 |
Metanium® |
At UHS, second line barrier preparation - for Critical Care and Child Health only
|
02.07.02 |
Metaraminol |
unlicensed
|
06.01.02.02 |
Metformin |
|
04.07.02 |
Methadone 10mg/ml |
Palliative Care only
|
04.10.03 |
Methadone 1mg/ml |
For management of opioid dependence only. |
03.09.01 |
Methadone Hydrochloride |
|
18 |
Methionine |
|
08.01.03 |
Methotrexate Haem/Onc |
|
10.01.03 |
Methotrexate Rheumatology |
ONCE WEEKLY
Specialist initiation (unless GP indicates preference to initiate therapy)
|
13.05.03 |
Methotrexate dermatology |
Once weekly.
|
13.05.02 |
Methoxypsoralen |
Dermatology only - for PUVA
Unlicensed
|
01.06.01 |
Methycellulose Celevac® |
|
13.08.01 |
Methyl aminolevulinate Metvix® |
Dermatology only
|
02.05.02 |
Methyldopa |
Antenatal use |
15.03 |
Methylene blue 0.5% Proveblue® |
Licensed for methaemoglobinaemia
Off-label use in septic shock, severe hypotension post-surgery and parathyroid surgery. |
04.04 |
Methylphenidate |
|
06.03.02 |
Methylprednisolone |
under specialist protocol for MS relapses
|
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® |
|
10.01.02.02 |
Methylprednisolone Acetate Depo-Medrone® with Lidocaine |
Pelvic pain clinic |
18 |
Methylthioninium chloride Proveblue® |
|
15.03 |
Methylthioninium chloride 1% inj Blue marker® |
Licensed as a medical device |
04.06 |
Metoclopramide |
Short term use only. No longer indicated as a motility stimulant |
02.02.01 |
Metolazone |
unlicensed
|
02.04 |
Metoprolol |
Tablets for initiation, review after 24 hours |
02.04 |
Metoprolol |
|
05.01.11 |
Metronidazole |
|
07.02.02 |
Metronidazole |
GUM only |
13.10.01.02 |
Metronidazole 0.75% |
Dermatology initiation for acute exacerbation of rosacea.
Also for fungating tumours. |
06.07.03 |
Metyrapone Metopirone® |
|
10.02.02 |
Mexiletine Namuscla® |
Commissioned by NHS England for patients with non-dystrophic myotonia within specialised neurosciences centres only
Note: mexiletine also approved locally as amber for cardiology use only (see section 2.3.2).
(167mg mexiletine = 200mg mexiletine hydrochloride) |
02.03.02 |
Mexiletine hydrochloride |
Cardiology use only unlicensed.
Note: also approved as red for myotonia (see section 10.2.2)
|
05.02.04 |
Micafungin |
Specialist use only
|
07.02.02 |
Miconazole |
|
12.03.02 |
Miconazole |
|
13.10.02 |
Miconazole 2% |
Can be purchased OTC.
|
15.01.04.01 |
Midazolam premedication/sedation |
Injection is for use in palliative care
Liquid is unlicensed |
15.01.04.01 |
Midazolam premedication |
for off-label use prior to endoscopy for adults and children >10 years who do not tolerate IV cannulation
See also section 4.8.2 |
04.08.02 |
Midazolam buccal liquid seizures |
unlicensed
Child Health only |
04.08.02 |
Midazolam oromucosal solution seizures |
Amber for children with a seizure disorder |
06.01.05 |
Midodrine |
|
08.01.05 |
Midostaurin |
|
08.02.04 |
Mifamurtide |
|
07.01.02 |
Mifepristone |
|
02.01.02 |
Milrinone Primacor® |
Critical Care only
|
02.05.01 |
Minoxidil |
|
07.04.02 |
Mirabegron |
Only if antimuscarinics are contraindicated or ineffective, or have unacceptable side effects
|
04.03.04 |
Mirtazapine |
Orodispersible tabs restricted to patients with swallowing difficulties |
07.01.01 |
Misoprostol |
For termination of pregnancy |
08.01.02 |
Mitomycin |
|
08.01.05 |
Mitotane |
palliative use in adrenal carcinoma |
08.01.02 |
Mitoxantrone |
|
15.01.05 |
Mivacurium Mivacron® |
Specialist use only
|
04.04 |
Modafinil |
Restricted use. For treatment of excessive sleepiness associated with narcolepsy only. Prescribing to be initiated by sleep specialist/neurologist.
Caution: prescribers should be aware of abuse risk (Modafinil: Be Smart) when considering quantities on prescriptions.
Modafinil is not supported for use (off-label) in any other indications in accordance with MHRA safety alert 2011.
|
A2.03.02 |
Modulen IBD ® |
Ordered via main stores |
12.02.01 |
Mometasone Furoate |
First line for children and for treatment of nasal polyps in adults
Second line to beclometasone propionate in adults for seasonal allergic or perennial rhinitis
|
13.04 |
Mometasone furoate 0.1% |
|
A2.03.01 |
Monogen® |
Ordered through main stores
400g |
03.03.02 |
Montelukast |
Granules for use only if unable to take alternative formulations
|
04.07.02 |
Morphine sulfate |
Zomorph capsules are first line oral morphine modified-releae product.
unlicensed suppositories
MR sachet (MST continous granules) discontinued in 2021 |
12.03.04 |
Mouthwash solution tab |
|
05.01.12 |
Moxifloxacin |
|
05.01.12 |
Moxifloxacin |
|
02.05.02 |
Moxonidine |
Specialist use only
|
A2.07 |
MSUD Anamix ® Infant |
Ordered via main stores |
09.06.07 |
Multivitamin |
|
09.06.07 |
Multivitamin preparations Abidec® |
Alternative to Dalivit drops on Neonatal Unit |
09.06.07 |
Multivitamin preparations Dalivit® |
|
12.02.03 |
Mupirocin 2% Bactroban Nasal® |
For MRSA only
|
13.10.01.01 |
Mupirocin 2% |
|
08.02.01 |
Mycophenolate mofetil |
Red for renal transplant
Amber for all other indications
Second line for resistant nephrotic syndrome, SLE nephritis |
08.02.01 |
Mycophenolate mofetil |
|
13.05.03 |
Mycophenolate sodium (mycophenolic acid) dermatology |
Dermatology only
Off label use
|
11.05 |
Mydricaine No. 2 |
Unlicensed
|
10.01.01 |
Nabumetone |
Not a first line NSAID |
02.06.04 |
Naftidrofuryl |
|
01.06.06 |
Naldemedine Rizmoic® |
|
04.10.01 |
Nalmefene |
Only in conjunction with continuous psychosocial support.
Shared care guidance can be found here |
01.06.06 |
Naloxegol Moventig ® |
|
15.01.07 |
Naloxone |
|
18 |
Naloxone |
|
04.10.01 |
Naltrexone Adepend® |
Recommended by alcohol detoxification service. |
04.10.03 |
Naltrexone Nalorex® |
|
10.01.01 |
Naproxen |
A first line NSAID |
08.02.04 |
Natalizumab |
|
04.07.01 |
Nefopam |
Restricted use
- Pain team use only
- Analgesic for post-operative acute pain when other analgesics (paracetamol, NSAIDS and opioids) are found to be ineffective, not tolerated or contraindicated.
- Not for use in chronic pain.
|
A2.03.01 |
Neocate® junior |
Ordered through main stores
400g |
A2.03.01 |
Neocate® LCP |
Ordered via main stores |
A2.03.01 |
Neocate® spoon |
Ordered through main stores |
05.01.04 |
Neomycin Sulphate |
Cancer care for gut sterilisation prior to BMT
Liquid is unlicensed
|
10.02.01 |
Neostigmine |
|
15.01.06 |
Neostigmine |
|
08.01.05 |
Neratinib Nerlynx® |
|
04.06 |
Netupitant and Palonosetron Akynzeo® |
For prevention of chemotherapy-induced nausea/vomiting |
05.03.01 |
Nevirapine |
|
02.06.03 |
Nicorandil |
For stable angina in accordance with NICE Guidelines |
04.10.02 |
Nicotine Replacement Therapy |
Formulary options - Nicotine patch [Nicorette Invisi patches]/Nicorette icy white gum/Nicorette inhalator/Nicorette Quickmist mouthspray.
As part of a smoking cessation programme. |
02.06.02 |
Nifedipine |
Prescribe by brand name, e.g. Adalat LA®, Adipine XL®, Coracten XL® |
02.06.02 |
Nifedipine |
Prescribe by brand name, e.g. Adalat Retard®, Adipine MR®, Coracten SR® |
02.06.02 |
Nifedipine |
Immediate release formulation for treatment of Raynaud's phenomenon.
Use in the treatment of autonomic dysreflexia is considered ‘off label’ use
Modified-release formulations preferred for other indications, including treatment of hypertension, angina prophylaxis and tocolysis.
Not recommended for (off label) sublingual administration.
|
07.01.03 |
Nifedipine |
Off-label use for tocolysis in accordance with UHS guideline
|
08.01.05 |
Nilotinib |
|
02.06.02 |
Nimodipine Nimotop® |
For subarachnoid haemorrhage |
02.06.02 |
Nimodipine Nimotop® |
For subarachnoid haemorrhage |
08.01.05 |
Nintedanib |
Vargatef branf for NSCLC, Ofev brand for IPF in line with NICE guidance (see links) |
08.01.05 |
Niraparib |
|
04.01.01 |
Nitrazepam |
|
05.01.13 |
Nitrofurantoin |
|
08.01.05 |
Nivolumab Opdivo® |
For untreated advanced renal cell carcinoma: available through Cancer Drugs Fund, only if conditions in the managed access agreement are followed. |
01.03.01 |
Nizatidine |
For use only as an alternative H2-antagonist when ranitidine is not available, and a proton pump inhibitor is not suitable.
|
07.03.03 |
Nonoxinol-9 |
|
02.07.02 |
Noradrenaline |
|
08.03.02 |
Norethisterone |
|
07.03.02.01 |
Norethisterone 350 microgram Noriday® |
|
06.04.01.02 |
Norethisterone 5mg |
Refer to Summary of Product Characteristics for licensed indications.
Not recommended for HRT (see WHO Evidence Summary). |
07.03.02.02 |
Norethisterone enantate Noristerat® |
For short term, interim contraception |
05.01.12 |
Norfloxacin |
|
14.05.01 |
Normal immunoglobulin for Intravenous use |
National Demand Management Programme - Request form must be completed
Specify brand
Specialist use only |
14.05.01 |
Normal immunoglobulin for Subcutaneous use |
National Demand Management Programme - Request form must be completed
Specify brand
Specialist use only |
10.02 |
Nusinersen Spinraza ® |
For use in spinal muscular atrophy (SMA) in line with NHSE specialised commissioning criteria
|
A2.03.01 |
Nutramigen® 1 with LGG |
Ordered via main stores |
A2.03.01 |
Nutramigen® Puramino |
Ordered via main stores |
A2.03.01 |
Nutricia® essential amino acid mix |
Ordered through main stores |
A2.01.03.04 |
Nutrini ® Energy Multifibre |
8 x 500ml stocked in pharmacy |
A2.01.03.02 |
Nutrini ®Multifibre |
8 x 500ml stocked in pharmacy.
For paediatric wards only |
A2.01.03.02 |
Nutrini ® |
8 x 500ml stocked in pharmacy
For paediatric wards only |
A2.01.03.01 |
Nutrini ®Low Energy Multifibre |
Not held in stock but available to order through pharmacy
Restricted to use in paediatrics only
12 x 200ml/8 x 500ml |
A2.01.03.02 |
Nutrini ®Peptisorb |
8 x 500ml stocked in pharmacy |
A2.01.03.04 |
Nutrini Energy ® |
8 x 500ml stocked in pharmacy
Paediatric wards only |
A2.01.03.04 |
Nutrini energy peptisorb® |
Not held in stock but available to order through pharmacy
8 x 500ml |
A2.03.01 |
Nutriprem 2 (Cow and Gate®) |
Ordered through main stores
90ml |
A2.05.02 |
Nutriprem Breast Milk Fortifier (Cow & Gate®) |
Ordered via main stores |
A2.03.01 |
Nutriprem protein supplement (Cow and Gate®) |
Ordered through main stores |
A2.01.03.01 |
Nutriprem® 2 |
|
A2.01.01.01 |
Nutrison ® |
8 x 500ml stocked in Pharmacy
8 x 1000ml 6 x 1500ml not held in stock but available to order through pharmacy |
A2.01.02.01 |
Nutrison ® Energy |
8 x 500ml stocked in pharmacy
8 x 1000ml/6 x 1500ml not held in stock but available to order through pharmacy |
A2.01.02.01 |
Nutrison ® Energy Multi Fibre |
8 x 500ml stocked in pharmacy
8 x 1000ml 6 x 1500ml not held in stock but available to order through pharmacy |
A2.01.02.02 |
Nutrison ® MCT |
8 x 1000ml stocked in pharmacy |
A2.01.01.01 |
Nutrison ® Multi Fibre |
8 x 500ml stocked in pharmacy
8 x 1000ml/6 x 1500ml not held in stock but available to order through pharmacy |
A2.01.02.02 |
Nutrison ® Protein Plus |
8 x 1000ml stocked in pharmacy |
A2.01.02.02 |
Nutrison ® Protein Plus Multi Fibre |
8 x 1000ml stocked in pharmacy |
A2.01.01.01 |
Nutrison ® Soya |
Not held in stock but available to order through pharmacy
8 x 1000ml |
A2.01.01.01 |
Nutrison ® Soya Multi Fibre |
Not held in stock but available to order through pharmacy
6 x 1500ml |
A2.01.02.02 |
Nutrison ® 1000 Complete Multi Fibre |
Not held in stock but available to order through pharmacy
8 x 1000ml |
A2.01.02.02 |
Nutrison ® 1200 Complete Multi Fibre |
Not held in stock but available to order through pharmacy
8 x 1000ml |
A2.02.02.01 |
Nutrison ® Energy Multi Fibre |
8 x 500ml stocked in pharmacy |
A2.01.01.01 |
Nutrison® Advanced Peptisorb |
8 x 500ml stocked in pharmacy
8 x 1000ml Not held in stock but available to order through pharmacy |
A2.01.02.03 |
Nutrison® Concentrated |
8 x 500ml stocked in pharmacy |
A2.01.01.01 |
Nutrison® Low Sodium |
8 x 1000ml stocked in pharmacy |
12.03.02 |
Nystatin |
|
01.09.01 |
Obeticholic acid Ocaliva® |
|
08.02.03 |
Obinutuzumab |
|
08.02.04 |
Ocrelizumab Ocrevus® |
|
11.08.02 |
Ocriplasmin Jetrea® |
|
13.11 |
Octenidine 0.3% Octenisan® |
From NHS logistics |
08.03.04.03 |
Octreotide |
|
08.03.04.03 |
Octreotide Sandostatin Lar® |
First choice for acromegaly
Shared Care Guideline for Lanreotide & Octreotide Long Acting Injection in Acromegaly (GP Summary) can be found here |
08.02.03 |
Ofatumumab |
|
05.01.12 |
Ofloxacin |
|
05.01.12 |
Ofloxacin |
|
11.03.01 |
Ofloxacin |
Ophthalmology only
|
01.07.03 |
Oily Phenol 5% |
|
04.02.01 |
Olanzapine |
Orodispersible tablets restricted to patients with swallowing difficulties |
08.01.05 |
Olaparib Lynparza® |
Note: NICE TA598 and TA620 only cover use of tablet formulation (not capsules)
Cancer Drugs Funding for 2nd line use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer (OLAP2) is under review and expected to be withdrawn March 2021 (see NICE GID-TA10712 and NHS England specialised commissioning circular SSC2225). Funding for use in 1st (OLAP1a and OLAP1b) and 3rd-line (OLAP3) settings will remain available. |
08.01.05 |
Olaratumab |
|
12.01.03 |
Olive Oil Ear Drops |
|
03.01.01.01 |
Olodaterol Striverdi Respimat® |
Prescribe by brand name.
Licensed for COPD only, not for asthma |
11.04.02 |
Olopatadine Opatanol® |
Ophthalmology only
|
03.04.02 |
Omalizumab Xolair® |
Occasionally used in primary care
NICE TA678 Omalizumab for treating chronic rhinosinusitis with nasal polyps
|
05.03.03.02 |
Ombitasvir/ paritaprevir/ ritonavir Viekirax® |
|
01.03.05 |
Omeprazole |
Dispersible tabs only for paediatric patients or patients with swallowing difficulties where dose is greater than 5mg.
|
01.03.05 |
Omeprazole 20mg in 5ml |
Child health use only
- Specialist recommendation only for paediatric patients under 1 year of age or under 10kg whereby dispersible tabs/esomeprazole sachets are not appropriate (i.e. prescribed dose under 5mg or feeding tube in situ)
- Available as licensed preparation (Rosemont), suitable for enteral tube administration. Powder should be reconstituted by pharmacist prior to dispensing to the patient (see product SPC).
If child is over 1 year and over 10kg with feeding tube - see esomeprazole granules sachets
Lansoprazole orodispersible tablets preferred in adults with swallowing difficulties/enteral tube administration.
|
04.06 |
Ondansetron |
|
04.09.01 |
Opicapone Ongentys® |
|
12.03.01 |
Orabase® |
Available OTC
|
09.02.01.02 |
Oral Rehydration Salts |
- Electrolade on FP10
|
03.04.02 |
Oralvac compact® |
unlicensed
Specialist allergy clinics only. For use only when licensed alternatives are not suitable.
|
04.05.01 |
Orlistat |
|
04.09.02 |
Orphenadrine |
|
05.03.04 |
Oseltamivir |
In line with NICE TAs or pandemic flu
|
08.01.05 |
Osimertinib |
|
08.01.05 |
Oxaliplatin |
|
06.04.03 |
Oxandrolone |
unlicensed
|
04.10.01 |
Oxazepam |
Off label use
UHS users see local guidelines |
04.08.01 |
Oxcarbazepine |
|
11.07 |
Oxybuprocaine Minims® |
|
07.04.02 |
Oxybutynin |
First line for urinary incontinence (refer to local guidelines and NICE CG171). May also be used for treatment of hyperhidrosis (off-label use).
Not suitable for frail older women or patients with cognitive impairment. |
07.04.02 |
Oxybutynin |
Transdermal only for patients unable to tolerate oral medicines (see NICE NG123)
|
07.04.02 |
Oxybutynin Lyrinel XL® |
MR tablets for existing patients only.
|
04.07.02 |
Oxycodone |
In UHS, liquid only for patients prescribed oxycodone MR due to intolerance to morphine, or for patients who require oral treatment after oxycodone PCA (Acute Pain Team recommendation only).
Capsules only for patients unable to tolerate liquid, not for ward stock
|
04.07.02 |
Oxycodone |
Amber for use in palliative care in the community, otherwise acute pain team only
Second line PCA
|
05.01.03 |
Oxytetracycline |
|
13.06.02 |
Oxytetracycline |
|
07.01.01 |
Oxytocin |
|
08.01.05 |
Paclitaxel |
|
08.01.05 |
Paclitaxel - Albumin Bound |
|
A2.02.01.01 |
Paediasure Peptide® |
200ml/500ml stocked in pharmacy.
Paediatric wards only |
A2.02.01.02 |
Paediasure Plus Juce® |
Not held in stock but available to order through pharmacy
200ml - Apple/Very Berry |
A2.01.03.04 |
Paediasure Plus® |
Not held in stock but available to order through pharmacy
200ml - Banana/Strawberry/Vanilla |
A2.04.02 |
Paediatric Seravit ® |
Not held in stock but available to order through pharmacy
200g |
08.01.05 |
Palbociclib Ibrance® |
|
04.02.02 |
Paliperidone palmitate Xeplion / Trevicta® |
Specialist use at Southern Health/Solent NHS Trust
For intramuscular injection. Xeplion = 1-monthly, Trevicta = 3-monthly maintenance dosing.
|
05.03.05 |
Palivizumab Synagis® |
Commissioned by NHS England (for RSV prophylaxis) for children in the groups outlined in Specialised Commissioning Circular 1937.
|
09.05.01.02 |
Pamidronate disodium |
|
01.09.04 |
Pancreatin Creon® |
|
01.09.04 |
Pancreatin Pancrex® V |
|
15.01.05 |
Pancuronium |
|
08.01.05 |
Panitumumab |
|
08.01.05 |
Panobinostat |
|
01.03.05 |
Pantoprazole |
|
02.06.04 |
Papaverine |
unlicensed
|
04.07.01 |
Paracetamol |
|
04.07.01 |
Paracetamol |
Injection only if oral/rectal routes are unavailable or inappropriate |
04.07.03 |
Paracetamol |
First line for neuropathic pain |
04.07.04.01 |
Paracetamol |
Soluble or dispersible form preferred +/- metoclopramide |
04.07.01 |
Paracetamol and codeine Co-codamol 30/500 |
Effervescent tablets restricted to patients with swallowing difficulties/enteral feeding tubes.
|
04.07.01 |
Paracetamol and codeine Co-codamol 8/500 |
Soluble preparations have a high sodium content |
04.07.01 |
Paracetamol and dihydrocodeine Co-dydramol 10/500 |
|
04.08.02 |
Paraldehyde and olive oil enema |
unlicensed
|
09.06.07 |
Paravit-CF |
Fat-soluble vitamin supplements for use when recommended by specialist in patients with cystic fibrosis.
Specialists to ensure preferred formulation and dose is clearly communicated to primary care prescribers. |
15.01.04.02 |
Parecoxib Dynastat® |
Off label use by subcutaneous injection/infusion in palliative care only; to be prescribed and administered under specialist supervision
|
03.12 |
PARI O-PEP® |
Oscillating Positive Expiratory Pressure (OPEP) device.
For initiation by specialist physiotherapist or respiratory clinician only. For airways clearance in selected patients with chronic sputum-producing lung disease, e.g. cystic fibrosis, bronchiectasis, COPD.
All follow up and monitoring of patients, and routine replacement of devices to be carried out in secondary care.
Primary care prescribing on FP10 only when required for urgent supply of additional/replacement device (Drug Tariff listed approved appliance). |
04.03.03 |
Paroxetine |
|
15.03 |
Patent Blue V® 2.5% |
unlicensed
Product of choice for sentinel lymph node biopsies |
09.02.01.01 |
Patiromer sorbitex calcium Veltassa® |
for acute use
for chronic use
For use only in accordance with recommendations in NICE TA623 |
08.01.05 |
Pazopanib |
|
08.01.05 |
Pegaspargase Oncaspar® |
|
09.01.06 |
Pegfilgrastim |
For sarcoma only
|
05.03.03 |
Peginterferon alfa-2a Pegasys® |
|
08.02.04 |
Peginterferon Alfa-2a Pegasys® |
|
05.03.03 |
Peginterferon Alfa-2b ViraferonPeg® |
|
08.02.04 |
Peginterferon Alfa-2b ViraferonPeg® |
|
08.02.04 |
Peginterferon Beta-1a Plegridy® |
Specialist use only
|
06.05.01 |
Pegvisomant Somavert® |
As per NHSE commissioning criteria
|
07.05 |
PelvicTonerTM device |
Medical device listed in Drug Tariff. Supported by District Prescribing Committee (Dec 2011) for prescribing in primary care only for use in accordance with NICE recommendations for management of urinary incontinence, as an aid to pelvic floor muscle training.
|
08.01.05 |
Pembrolizumab Keytruda® |
50mg powder for concentrate for solution for infusion is black triangle
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma - not recommended
Note: Funding from the Cancer Drugs Fund for 1st line use in urothelial cancer has been ceased from 17th Feb 2021 following publication of NICE terminated guidance (NICE TA674)- NICE TA522 has been replaced.
|
08.01.03 |
Pemetrexed |
|
10.01.03 |
Penicillamine |
|
11.03.01 |
Penicillin G (Benzylpenicillin) |
unlicensed
Ophthalmology only
|
05.04.08 |
Pentamidine Isetionate |
|
07.04.03 |
Pentosan polysulfate sodium Elmiron® |
DPC April 2018 for bladder pain syndrome/interstitial cystitis |
A2.03.01 |
Pepdite 1+ |
Ordered through main stores |
01.02 |
Peppermint Oil Mintec® |
|
A2.01.02.02 |
Peptamen ® HN |
Not held in stock but available to order through pharmacy
500ml |
A2.01.02.01 |
Peptamen® AF |
Not held in stock but available to order through pharmacy
500ml |
A2.03.01 |
Peptamen® junior |
Ordered through main stores |
04.08.01 |
Perampanel Fycompa® |
Treatment initiated and patients stabilised by neurology specialists
|
11.08.02 |
Perfluorodecalin (perflunafene) |
unlicensed
|
04.09.01 |
Pergolide |
|
01.06.05 |
Peristeen® anal irrigation system |
Approved appliance (refer to part IX of NHS England and Wales Drug Tariff)
For neurogenic bowel dysfunction |
13.10.04 |
Permethrin 5% |
First line for scabies.
Self Care Medicine. Can be purchased OTC.
|
08.01.05 |
Pertuzumab Perjeta® |
|
08.01.05 |
Pertuzumab/trastuzumab Phesgo® |
From 10/02/2021 NHS England and Improvement will commission the new combined pertuzumab and trastuzumab subcutaneous injection, brand name PHESGO®, for all existing pertuzumab and trastuzumab indications as an alternative to IV pertuzumab and trastuzumab (NICE TA424, NICE TA509, NICE TA569)
This product is for subcutaneous use only
|
04.07.02 |
Pethidine |
|
04.07.02 |
Pethidine |
|
04.03.02 |
Phenelzine Nardil® |
Specialist use only
|
02.08.02 |
Phenindione |
|
04.08.01 |
Phenobarbital |
Child Health and existing patients only
|
04.08.02 |
Phenobarbital |
|
04.08.01 |
Phenobarbital elixir |
unlicensed
Specialist use only
|
13.11.05 |
Phenol Swabs Swab-it® |
For nail matrixectomy (ingrown nail removal or ablations)
(medical device) |
02.05.04 |
Phenoxybenzamine Hydrochloride |
|
05.01.01.01 |
Phenoxymethylpenicillin penicillin V |
|
02.05.04 |
Phentolamine |
unlicensed
Critical Care only
|
10.01.01 |
Phenylbutazone |
Specialist use only
|
02.07.02 |
Phenylephrine |
First line for acute hypotension |
11.05 |
Phenylephrine Minims® |
Preservative-free.
10% eye drops contra-indicated in children and the elderly.
Patients should be warned not to undertake skilled tasks (e.g. driving) until vision clears after mydriasis.
|
11.05 |
Phenylephrine and tropicamide ophthalmic insert Mydriasert® |
|
04.07.03 |
Phenytoin |
For trigeminal neuralgia if carbamazepine is ineffective or not tolerated |
04.08.01 |
Phenytoin |
Preparations containing phenytoin sodium are not bioequivalent to those containing phenytoin base. |
04.08.02 |
Phenytoin |
|
02.03.02 |
Phenytoin sodium |
Cardiology use only
|
03.09.01 |
Pholcodine Linctus, BP |
|
09.05.02.01 |
Phosphate supplements Phosphate-Sandoz® |
|
01.06.04 |
Phosphates (Rectal) |
|
02.08.03 |
Phytomenadione Konakion MM ® |
Konakion MM Paediatric injection can be given orally |
09.06.06 |
Phytomenadione Neokay |
TTO use only
The contents of one capsule should be administered by cutting the narrow tubular tip off and squeezing the liquid contents into the mouth. |
09.06.06 |
Phytomenadione |
Tablets are unlicensed
Konakion MM paediatric injection can be given orally |
01.06.05 |
Picolax ® |
|
11.06 |
Pilocarpine |
|
11.06 |
Pilocarpine 2% |
Preservative-free.
Only for patients allergic/intolerant of preservatives, or high risk of developing allergy.
|
13.05.03 |
Pimecrolimus Elidel® |
|
06.01.02.03 |
Pioglitazone |
|
05.01.01.04 |
Piperacillin and Tazobactam |
|
04.02.02 |
Pipotiazine palmitate Piportil® Depot |
Southern Health only
For deep intramuscular injection
|
04.09.03 |
Piracetam Nootropil® |
Specialist initiation only
For the treatment of severe myoclonic epilepsy |
04.12 |
Pirenzepine |
Specialist use at Southern Health only.
unlicensed
|
03.11 |
Pirfenidone |
|
04.04 |
Pitolisant Wakix® |
Restricted use. For specialist sleep clinic use for treatment of narcolepsy in patients aged ≥18 years, only when conventional stimulants have failed/not tolerated, and sodium oxybate is not suitable/not tolerated as per DPC recommendations.
|
05.01.01.05 |
Pivmecillinam |
Microbiology recommendation only
|
08.01.02 |
Pixantrone |
|
04.07.04.02 |
Pizotifen |
|
A2.07 |
PKU Anamix ® Infant |
Ordered via main stores |
09.02.02.01 |
Plasma-Lyte 148; Plasma-Lyte 148 with Glucose 5% |
For use in Southampton Children’s Hospital as alternative to compound sodium lactate (Hartmann’s) and as standard fluid of choice.
Contains potassium (K+) 5mmol/L
|
13.14 |
Plaster remover |
|
09.01.07 |
Plerixafor |
For use as per commissioning criteria set by NHS England |
14.04 |
Pneumococcal polysaccharide conjugate vaccine (13-valent adsorbed) |
|
13.07 |
Podophyllin Compound Paint BP |
Contains podophyllum resin 0.15% w/v.
|
13.07 |
Podophyllotoxin 0.15% |
|
13.07 |
Podophyllotoxin 0.5% |
|
08.01.05 |
Polatuzumab vedotin Polivy® |
|
11.03.01 |
Polihexanide (Polyhexamethylene) PHMB |
unlicensed
Ophthalmology only
|
06.01.06 |
Polycal ® |
|
A2.04.01.01 |
Polycal ® |
Not held in stock but available to order through pharmacy
200ml - Neutral
Polycal powder ordered via main stores |
14.04 |
Polysaccharide Typhoid Vaccine |
|
11.08.01 |
Polyvinyl alcohol 1.4% Liquifilm Tears or Sno Tears® |
To be used in line with DPC dry eye guidelines (link below)
Unit dose drops only for patients allergic/intolerant of preservatives or high risk of developing allergy
|
08.02.04 |
Pomalidomide Imnovid® |
|
08.01.05 |
Ponatinib |
|
03.05.02 |
Poractant Alfa |
Neonatal unit only
|
05.02.01 |
Posaconazole |
Specialist use only
|
11.99.99.99 |
Potassium ascorbate (ascorbic acid) |
Unlicensed special
Preservative-free. For chemical burns.
|
02.02.03 |
Potassium canrenoate |
unlicensed
|
09.02.01.01 |
Potassium Chloride Sando-K® |
|
09.02.01.01 |
Potassium Chloride Kay-Cee-L® |
|
09.02.01.01 |
Potassium Chloride Slow-K® |
|
09.02.02.01 |
Potassium Chloride and Glucose Intravenous Infusion |
Potassium chloride 0.2% and glucose 5% (containing approx. 13.5mmol potassium chloride) 500ml bags
Potassium chloride 0.2% and glucose 5% (containing approx. 27mmol potassium chloride) 1L bags
Potassium chloride 0.3% and glucose 5% (containing 40mmol potassium chloride) 1L bags |
09.02.02.01 |
Potassium Chloride and Sodium Chloride Intravenous Infusion |
Potassium chloride 0.15%, sodium chloride 0.45% and glucose 5% (containing 10mmol potassium chloride) 500ml bags
Potassium chloride 0.15%, sodium chloride 0.45% and glucose 10% (containing 10mmol potassium chloride) 500ml bags
Potassium chloride 0.15%, sodium chloride 0.18% and glucose 10% (containing 10mmol potassium chloride) 500ml bags
Potassium chloride 0.2% and glucose 5% (containing approx. 13.5mmol potassium chloride) 500ml bags
Potassium chloride 0.2% and glucose 5% (containing approx. 27mmol potassium chloride) 1L bags
Potassium chloride 0.2% and sodium chloride 0.9% (containing approx. 13.5mmol potassium chloride) 500ml bags
Potassium chloride 0.2% and sodium chloride 0.9% (containing approx. 27mmol potassium chloride) 1L bags
Potassium chloride 0.2%, glucose 4% and sodium chloride 0.18% (containing approx. 13.5mmol potassium chloride) 500ml bags
Potassium chloride 0.2%, glucose 4% and sodium chloride 0.18% (containing approx. 27mmol potassium chloride) 1L bags
Potassium chloride 0.3% and sodium chloride 0.9% (containing 20mmol potassium chloride) 500ml bags
Potassium chloride 0.3% and sodium chloride 0.9% (containing 40mmol potassium chloride) 1L bags
Potassium chloride 0.3%, sodium chloride 0.45% and glucose 5% (containing 20mmol potassium chloride) 500ml bags |
07.04.03 |
Potassium Citrate |
|
13.11.06 |
Potassium permanganate Permitabs® |
Should be dispensed in original container (i.e. as whole pack) only (see safety bulletin on risks of accidental ingestion below).
|
13.11.04 |
Povidone iodine 10% |
From NHS Logistics. |
13.11.04 |
Povidone iodine 10% |
From NHS Logistics. |
12.04 |
Povidone iodine 10% in boric acid powder |
Unlicensed
|
13.11.04 |
Povidone iodine 2.5% |
|
13.11.04 |
Povidone iodine 7.5% |
From NHS Logistics. |
18 |
Pralidoxime chloride Protopam® |
|
04.09.01 |
Pramipexole |
Check base/salt equivalence
|
04.09.04 |
Pramipexole |
Specialist use only
Third/fourth line for restless legs syndrome |
02.09 |
Prasugrel Efient® |
|
02.12 |
Pravastatin |
|
01.05.02 |
Prednisolone |
Rectal foam for use in paediatrics only
|
06.03.02 |
Prednisolone |
Not enteric coated tablets
See DPC Summary June 2018 for recommendations on dissolving or crushing plain prednisolone tablets. |
10.01.02.01 |
Prednisolone |
Not EC tablet |
11.04.01 |
Prednisolone |
0.5% prednisolone sodium phosphate solution/unit dose preparations: prescribe generically.
1% prednisolone acetate: prescribe as Pred Forte®
|
04.07.03 |
Pregabalin |
For neuropathic pain in accordance with NICE Guidelines
Also amber for epilepsy and green for generalised anxiety disorder (see section 4.8.1)
Oral solution high cost - for use only when capsules not suitable (note: capsules can be opened and contents dispersed in water for patients with swallowing difficulties/feeding tubes)
|
04.08.01 |
Pregabalin |
Amber for epilepsy (not a first line choice)
Green for generalised anxiety disorder
Also green for neuropathic pain (see section 4.7.3)
Oral solution high cost - for use only when capsules not suitable (note: capsules can be opened and contents dispersed in water for patients with swallowing difficulties/feeding tubes)
|
A2.03.01 |
Pregestimil ® lipil |
Ordered via main stores |
A2.03 |
preOP® |
24 x 200ml stocked in pharmacy
For enhanced recovery surgery |
15.02 |
Prilocaine Hydrochloride 1%/2% |
|
15.02 |
Prilocaine Hydrochloride with Felypressin |
|
05.04.01 |
Primaquine |
unlicensed
microbiology recommendation only
|
05.04.08 |
Primaquine |
unlicensed
|
04.08.01 |
Primidone |
Existing patients only |
02.03.02 |
Procainamide |
unlicensed.
Cardiology use only.
|
08.01.05 |
Procarbazine |
|
04.06 |
Prochlorperazine |
Buccal tabs are an alternative to injectable antiemetics. |
01.07.02 |
Proctosedyl ® |
Local anaesthetic plus steroid |
04.09.02 |
Procyclidine |
|
13.10.05 |
Proflavine 0.1% |
|
06.04.01.02 |
Progesterone (micronised) 100mg Utrogestan® |
For oral administration as HRT. |
06.04.01.02 |
Progesterone (micronised) 200mg Utrogestan ® |
For emergency supply to patients treated by the fertility unit only
|
06.04.01.02 |
Progestogen pessaries |
|
05.04.01 |
Proguanil Hydrochloride with Atovaquone Malarone® |
|
04.02.01 |
Promazine Hydrochloride |
Injection is unlicensed |
03.04.01 |
Promethazine |
|
03.04.01 |
Promethazine |
|
04.06 |
Promethazine |
- 10mg, 25mg tablets
- 5mg/5ml elixir
|
02.03.02 |
Propafenone |
Cardiology only.
|
11.03.01 |
Propamidine isetionate Brolene® |
'Off label' use for Acanthamoeba infections |
01.02 |
Propantheline bromide |
Also off-label for diabetic neuropathy |
13.12 |
Propantheline bromide Pro-Banthine® |
For hyperhidrosis (licensed indication), or consider oxybutynin or trospium (off-label).
|
15.01.01 |
Propofol |
|
02.04 |
Propranolol |
|
02.04 |
Propranolol |
unlicensed
|
04.07.04.02 |
Propranolol |
|
06.02.02 |
Propranolol |
For rapid relief of thyrotoxic symptoms |
06.02.02 |
Propranolol |
For rapid relief of thyrotoxic symptoms |
11.08.01 |
Propylene glycol 0.3% and polyethylene glycol 0.4% Systane® Preservative-free |
To be used in line with DPC dry eye guidelines (link below)
Only for patients requiring a preservative-free alternative to propylene glycol [Systane Balance] eye drops
|
11.08.01 |
Propylene glycol 0.6% Systane Balance® |
To be used in line with DPC dry eye guidelines (link below)
|
13.02.01 |
Propylene glycol in aqueous cream |
From British Association of Dermatologists (BAD) Specials List 2014.
Unlicensed.
Dermatology recommendation only.
Use when urea based products are ineffective, unsuitable or not tolerated.
Can also be used as a barrier cream |
06.02.02 |
Propylthiouracil |
|
A2.04.01.03 |
ProSource ® TF Liquid |
Not held in stock but available to order through pharmacy
100 x 45ml |
02.08.03 |
Protamine sulfate |
|
06.01.06 |
Protein test strips Albustix® |
|
06.05.01 |
Protirelin TRH |
unlicensed
|
11.07 |
Proxymetacaine Minims® |
|
01.06.07 |
Prucalopride Resolor® |
|
03.10 |
Pseudoephedrine Hydrochloride |
Off-label use for emergency treatment of priapism |
05.01.09 |
Pyrazinamide |
|
10.02.01 |
Pyridostigmine Bromide |
|
04.08.02 |
Pyridoxine |
unlicensed
Child Health only.
|
09.06.02 |
Pyridoxine Hydrochloride |
|
05.04.07 |
Pyrimethamine |
|
05.04.01 |
Pyrimethamine with Sulfadoxine |
unlicensed
|
04.02.01 |
Quetiapine |
|
05.04.01 |
Quinine dihydrochloride |
unlicensed
|
05.04.01 |
Quinine sulfate |
|
10.02.02 |
Quinine sulfate |
|
14.05.02 |
Rabies immunoglobulin |
Microbiology request only |
14.04 |
Rabies vaccine |
Restricted for use in line with post-exposure prophylaxis guidelines only (see staffnet)
|
08.03.04.02 |
Radium-223 dichloride |
Radiopharmaceutical to be administered only by authorised persons |
06.04.01.01 |
Raloxifene Hydrochloride |
Osteoporosis - Second line |
05.03.01 |
Raltegravir |
|
02.05.05.01 |
Ramipril |
|
11.08.02 |
Ranibizumab |
|
01.03.01 |
Ranitidine |
|
01.03.01 |
Ranitidine |
|
02.06.03 |
Ranolazine Ranexa® |
Specialist recommendation only. Third-line option for stable angina where other anti-anginals are contraindicated/not tolerated due to hypotensive and/or bradycardic effects and revascularisation options not available.
|
04.09.01 |
Rasagiline |
First choice MAO-B inhibitor |
10.01.04 |
Rasburicase Fastertec® |
Oncology only |
04.03.04 |
Reboxetine |
|
02.14 |
Regadenoson |
unlicensed
For use during radionuclide myocardial perfusion scanning |
08.01.05 |
Regorafenib Stivarga® |
|
05.03 |
Remdesivir Veklury® |
For use only in the treatment of patients hopitalised with suspected or laboratory-confirmed SARS-CoV-2 (COVID -19) infection who meet the clinical criteria.
Approved in accordance with the interim clinical commissioning policy for the treatment of COVID-19
See Management of COVID-19 patients (via UHS staffnet) for the treatment and supply process |
15.01.04.03 |
Remifentanil Ultiva® |
Theatres and patient controlled analgesia during labour
|
A2.03.02 |
Renastart ® |
Ordered via main stores |
03.04.02 |
Reslizumab |
|
02.10.02 |
Reteplase Rapilysin® |
|
05.03.03.02 |
Ribavirin |
|
05.03.05 |
Ribavirin |
Specialist use only
Injection is unlicensed
|
08.01.05 |
Ribociclib Kisqali® |
|
05.01.09 |
Rifabutin |
For mycobacterium avium prophylaxis |
05.01.10 |
Rifampicin |
Red for tuberculosis
Amber for other infections
|
05.01.09 |
Rifampicin and Isoniazid |
|
05.01.09 |
Rifampicin, Isoniazid and Pyrazinamide Rifater® |
|
05.01.09 |
Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv® |
|
05.01.07 |
Rifaximin |
for hepatic encephalopathy- see shared care guidance (link below)
Third line treatment for small intestine bacterial overgrowth. Specialist use only as per UHS guideline
|
05.03.01 |
Rilpivirine hydrochloride |
|
04.09.03 |
Riluzole Rilutek® |
|
09.02.02.01 |
Ringers Solution |
|
10.02 |
Risdiplam |
For the treatment of type 1 and type 2 Spinal Muscular Atrophy (SMA) in patients 2 months and older who are not suitable for authorised treatments. Specialist use only. Available via MHRA EAMS application for eligible patients.
EAMS available here |
06.06.02 |
Risedronate |
|
04.02.01 |
Risperidone |
Orodispersible tablets restricted to patients with swallowing difficulties |
04.02.02 |
Risperidone Risperdal Consta® |
Psychiatry only
For deep intramuscular injection
|
05.03.01 |
Ritonavir |
|
08.02.03 |
Rituximab/ rituximab biosimilar MabThera®, Rixathon®, Truxima®) (Haematology |
Specialist use only
Also for ITP and refractory autoimmune haemolytic anaemia
Specify brand.
Rixathon and Truxima black triangle
|
10.01.03 |
Rituximab/rituximab biosimilar MabThera®, Rixathon®, Truxima®) (Rheumatology & Other |
Also for pemphigus vulgaris (MabThera brand only).
off label use in pemphigoid; nephrotic syndrome (children); systemic lupus erythematosus in adults/post-pubescent children; anti-NMDAR autoimmune encephalitis (all ages); immunoglobulin G4-related disease.
Not routinely commissioned for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), vasculitis of the peripheral nervous system & IgM paraprotein-associated demyelinating neuropathy (adults) or for connective tissue disease associated with interstitial lung disease - see NHS England Commissioning Policies.
Specify brand
Rixathon and Truxima black triangle
|
02.08.02 |
Rivaroxaban Xarelto®) (AF/VTE |
|
02.08.02 |
Rivaroxaban Xarelto®) (Orthopaedic prophylaxis |
- red for trauma (off-label use)
- red for off-label use for patients with fractured neck of femur or who have a plaster cast and who fulfil the assessment criteria
|
02.08.02 |
Rivaroxaban Xarelto®) (ACS |
|
04.11 |
Rivastigmine |
Liquid only for patients unable to swallow capsules
Also for dopaminergic drug-induced psychosis as 'Off-label use' |
15.01.05 |
Rocuronium Esmeron® |
|
03.03.03 |
Roflumilast |
|
09.01.04 |
Romiplostim Nplate® |
|
04.09.01 |
Ropinirole |
An initial choice, particularly in younger patients.
|
02.12 |
Rosuvastatin |
Reserved for use in patients requiring high intensity statin unable to tolerate/unsuitable for atorvastatin or high dose simvastatin
|
14.04 |
Rotavirus vaccine Rotarix® |
|
04.09.01 |
Rotigotine |
Initiated/recommended by specialists only.
A replacement for oral dopamine agonists in patients with inadequate control of nocturnal/early morning symptoms.
In patients with inadequate compliance of complex regimens (cognitive problems, unable to swallow oral medication, motor problems).
As sole treatment in emergency situations when patients are unable to swallow oral drugs |
08.01.05 |
Rucaparib Rubraca® |
|
04.08.01 |
Rufinamide Inovelon® |
Initiated by Paediatric Neurologists for Lennox Gastaut syndrome
|
02.11 |
Rurioctocog alfa pegol Adynovi® |
Haematology specialist use only under NHS England specialised commissioning arrangements.
|
08.01.05 |
Ruxolitinib Jakavi® |
Commissioned by NHSE in line with NICE TA and treatment criteria detailed in Cancer Drugs Fund list or on Blueteq application forms.
|
02.05.05.02 |
Sacubitril valsartan Entresto® |
|
04.09.01 |
Safinamide |
Restricted to use in late-stage Parkinson’s Disease and motor fluctuations where treatment with rasagiline/selegiline and entacapone has failed/not tolerated
|
03.01.01.01 |
Salbutamol |
Prescribe breath-actuated MDIs and DPIs by brand name
|
13.07 |
Salicylic acid |
May be purchased OTC.
For palmar/plantar warts, corns, calluses. |
13.07 |
Salicylic acid |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05 |
Salicylic acid 2% & sulphur 2% |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
13.05 |
Salicylic acid 2%/5%/10%/20% |
From British Association of Dermatologists (BAD) Specials List 2014.
Unlicensed
|
13.04 |
Salicylic acid 5%, with propylene glycol 47.5% in clobetasol propionate 0.05% (Dermovate®) |
Dermatology recommendation only
Refer to British Association of Dermatologists Specials List 2014 for further details
unlicensed
|
13.07 |
Salicylic acid with lactic acid Salactol® |
May be purchased OTC
For palmar/plantar warts, corns, calluses. |
03.01.01.01 |
Salmeterol |
Prescribe by brand name.
DPI = Serevent Accuhaler |
05.03.01 |
Saquinavir |
|
10.01.03 |
Sarilumab Kevzara® |
Also available as a treatment option through routine commissioning for adult patients hospitalised with COVID-19 (off label use) in accordance with the criteria set out in the NHS England interim clinical commissioning policy document (see link below)
|
A2.04.01.02 |
Scandishake ® |
6 x 85g stocked in pharmacy
Chocolate, Strawberry, Vanilla
Unflavoured/Caramel/Banana - not held in stock but available to order through pharmacy |
10.01.03 |
Secukinumab Cosentyx®) (Rheumatology |
Rheumatology indications |
13.05.03 |
Secukinumab Cosentyx®) (dermatology |
|
04.09.01 |
Selegiline Hydrochloride |
|
09.05.05 |
Selenium and vitamins A,C and E |
Approved for use at UHS on Intensive Care only
Not a licensed medicine - nutritional supplement.
Not prescribable on FP10
|
06.01.02.03 |
Semaglutide Ozempic® /Rybelsus® |
(injection/tablet):
- Type 2 diabetes mellitus [monotherapy (if metformin inappropriate) or in combination with other antidiabetic drugs] in adults.
Injection: Once weekly formulation.
Tablets are not recommended as FIRST-LINE. Tablets should be restricted to those that are unsuitable for the subcutaneous GLP-1RA injection preparations e.g. due to difficulty in administration, needle phobic etc.
- Tablets should be taken on empty stomach with a sip of water. Due to decreased absorption, patients should wait at least 30 minutes before eating or drinking or taking other oral medicinal products.
- Due to the high pharmacokinetic variability of oral semaglutide, the effect of switching between oral and subcutaneous semaglutide cannot easily be predicted. Request specialist advice if seeking to switch patients from injectable to oral.
(injection only) For use in childen :
-
Type 2 diabetes mellitus in children ≥10y, not adequately controlled with diet, exercise, and metformin alone (or where metformin is contraindicated or not tolerated).
-
Severe obesity in children ≥10y with comorbidities, where
a) Weight management is not adequately controlled with diet, exercise, and metformin (or where metformin is contraindicated or not tolerated), or
b) Exceptional circumstances prevent adherence to the above measures (e.g., severely autism, severe learning disabilities, immobility).
|
01.06.02 |
Senna |
|
04.03.03 |
Sertraline |
|
09.05.02.02 |
Sevelamer Carbonate |
Only when calcium-containing products not tolerated |
09.05.02.02 |
Sevelamer Hydrochloride Renagel® |
Only when calcium-containing products not tolerated |
15.01.02 |
Sevoflurane |
For children, patients with liver failure or obesity
|
02.05.01 |
Sildenafil Revatio® |
Specialist use only. Pulmonary hypertension.
|
02.06.04 |
Sildenafil |
Off label use
An option in patients with Raynaud’s phenomenon- shared care guidance can be found here |
07.04.05 |
Sildenafil |
First-line PDE5 inhibitor, including post-prostatectomy. Prescribe as generic, on-demand. Regular use not supported (DPC recommendations Aug 2014).
Green for ED
Amber for severe Raynaud's associated with scleroderma (see shared care guideline)
|
07.04.05 |
Sildenafil |
Specialised commissioning for paediatrics
|
11.08.02 |
Silicone fluid 5700 CS liq |
unlicensed
|
13.07 |
Silver nitrate ('caustic') |
|
13.10.01.01 |
Silver sulfadiazine 1% Flamazine® |
For infected burns and ulcers
|
05.03.03.02 |
Simeprevir |
|
01.01.01 |
Simeticone infacol® |
For use during endoscopy Unlicensed |
A2.03.01 |
Similac Alimentum® |
Ordered via main stores |
03.09.02 |
Simple Linctus, BP |
|
02.12 |
Simvastatin |
|
12.04 |
Sinus Rinse |
|
08.02.04 |
Siponimod Mayzent® |
|
08.02.02 |
Sirolimus |
Red for renal transplant
Amber for liver transplant
|
06.01.02.03 |
Sitagliptin |
|
A2.03.01 |
SMA® 1 ready to feed |
Ordered through main stores
100mls x 24 |
A2.03.01 |
SMA® Althera |
Ordered through main stores
450g |
A2.03.01 |
SMA® high energy ready to feed |
Ordered through main stores
100mls x 24 |
A2.03.01 |
SMA® lactose free |
Ordered through main stores
430g |
18 |
Snakebite Antivenom Serum Adder |
|
A2.03.01 |
Sno-Pro® |
Not held in stock but available to order through pharmacy
200ml |
09.08.01 |
Sodium Benzoate |
unlicensed
|
09.02.01.03 |
Sodium Bicarbonate |
|
09.02.02.01 |
Sodium bicarbonate |
Sodium bicarbonate 1.26%, 1.4%, 2.74%, 4.2% intravenous infusion
Sodium bicarbonate 8.4% intravenous infusion |
12.01.03 |
Sodium Bicarbonate |
|
18 |
Sodium calcium edetate |
|
09.02.01.02 |
Sodium Chloride Slow Sodium® |
|
07.04.04 |
Sodium chloride 0.9% |
|
12.02.02 |
Sodium chloride 0.9% |
|
13.11.01 |
Sodium chloride 0.9% Normal saline |
For wound irrigation.
Refer to Wound Formulary for further details.
|
11.99.99.99 |
Sodium chloride 0.9% (saline) unit dose eye drops Minims |
Preservative-free |
03.07 |
Sodium chloride 3% (Hypertonic saline) |
Specialist use only
|
11.99.99.99 |
Sodium Chloride 5% eye drops/ eye ointment |
Eye ointment unlicensed
|
03.07 |
Sodium chloride 7% (Hypertonic saline) |
Prescribe by brand name for CF |
09.02.02.01 |
Sodium Chloride and Glucose Intravenous Infusion |
Sodium chloride 0.18% and glucose 4% intravenous infusion
Sodium chloride 0.45% and glucose 2.5% intravenous infusion
Sodium chloride 0.45% and glucose 5% intravenous infusion
Sodium chloride 0.9% and glucose 5% intravenous infusion |
09.02.02.01 |
Sodium Chloride Intravenous |
Sodium chloride 0.45% intravenous infusion
Sodium chloride 0.9% intravenous infusion
Sodium chloride 5% intravenous infusion |
15.03 |
Sodium citrate 0.3M |
For prevention of aspiration pneumonitis prior to general anaesthesia for emergency caesarean section |
01.06.04 |
Sodium Citrate enema |
Micolette enema (FP10) |
06.06.02 |
Sodium clodronate |
|
03.03.01 |
Sodium Cromoglicate |
|
11.04.02 |
Sodium cromoglicate |
First line for allergic conjunctivitis and seasonal keratoconjunctivitis
Unit dose formulation only for patients allergic to preservatives
Sodium cromoglicate 2% eye drops (in max. pack size 10 mL) can be sold to the public for treatment of acute seasonal and perennial allergic conjunctivitis. Conditions for which over the counter items should not routinely be prescribed in primary care.
|
09.01.01.01 |
Sodium feredetate 190mg/5ml |
Contains 27.5mg elemental iron per 5ml |
13.10.01.02 |
Sodium fusidate 2% Fucidin® |
|
05.01.07 |
Sodium fusidate/fusidic acid |
|
09.05.02.01 |
Sodium glycerophosphate 21.6% Glycophos® |
unlicensed
First line intravenous choice |
07.04.04 |
Sodium hyaluronate Hyacyst® |
Urology specialist only
|
11.08.01 |
Sodium hyaluronate |
For use in line with DPC dry eye guidelines (link below)
Various brands available - refer to Drug Tariff for current prices in primary care. |
11.08.02 |
Sodium hyaluronate 1% Provisc® |
Ophthalmology only
First line for routine cataract surgery cases.
|
11.08.02 |
Sodium hyaluronate 1% Healonid® |
Ophthalmology only
Corneal grafts or other corneal surgery
|
11.08.02 |
Sodium hyaluronate 1.4% Healonid GV |
Ophthalmology only
Second line for more complex cataract surgery cases
|
07.04.04 |
Sodium hyaluronate and sodium chondroitin iAluRil® |
Urology specialist only
|
01.06.07 |
Sodium hydrogen carbonate / sodium dihydrogen phosphate Lecicarbon A® |
As per UHS chronic constipation guidelines |
18 |
Sodium nitrite |
|
02.05.01 |
Sodium nitroprusside |
unlicensed
Critical Care and Child Health nephrology only
|
04.04 |
Sodium Oxybate Xyrem® |
As per NHS England clinical commissioning criteria for use in children (≤18 years).
Adult use (≥19 years) requires IFR submission to CCG. |
09.08.01 |
Sodium Phenylbutyrate |
unlicensed
|
01.06.02 |
Sodium Picosulfate |
|
02.13 |
Sodium Tetradecyl Sulphate Fibro-Vein® |
|
18 |
Sodium thiosulphate |
|
04.02.03 |
Sodium valproate |
Agreed locally for ‘off-label’ use in treatment of manic episodes in bipolar disorder instead of valproate semisodium.
Brand prescribing is not necessary for this indication.
|
04.08.01 |
Sodium Valproate |
For primary generalised epilepsy (including absences and myoclonus), partial seizures, secondary generalised tonic-clonic seizures |
09.02.01.01 |
Sodium zirconium cyclosilicate Lokelma |
For use only in accordance with recommendations in NICE TA599 |
05.03.03.02 |
Sofosbuvir |
|
05.03.03.02 |
Sofosbuvir with velpatasvir Epclusa® |
|
05.03.03.02 |
Sofosbuvir/velpatasvir/voxilaprevir Vosevi |
|
10.01.03 |
Soldium Aurothiomalate Myocrisin® |
|
07.04.02 |
Solifenacin |
|
07.04.04 |
Solution G |
|
06.05.01 |
Somatropin |
First line choices are Genotropin or Omnitrope. |
08.01.05 |
Sorafenib |
|
02.03.02 |
Sotalol |
|
02.02.03 |
Spironolactone |
|
05.03.01 |
Stavudine |
|
13.11.07 |
Sterile larvae Maggots |
Specialist use only
|
15.03 |
Sterile talc kit |
Specialist use only |
12.04 |
Sterimar |
For short-term use after ENT surgery only
|
04.08.01 |
Stiripentol Diacomit® |
Specialist initiation only.
Amber Initiation - for the treatment of severe myoclonic epilepsy.
Amber Shared Care Guidelines - for Dravet syndrome in children aged 3 years or older, adolescents and adults, in accordance with NICE guidelines CG137.
|
01.08 |
Stoma Care |
Contact the Intestinal Failure Unit on 023 8120 6510 |
02.10.02 |
Streptokinase |
|
05.01.09 |
Streptomycin |
unlicensed
|
08.01.05 |
Streptozocin |
unlicensed
Locally advanced and metastatic neuroendocrine tumours |
01.03.03 |
Sucralfate |
tablets are unlicensed
Suspension is licensed, therefore this is the formulation of choice.
|
13.02.02 |
Sudocrem® |
|
15.01.06 |
Sugammadex Bridion® |
Consultant anaesthetist use only
|
13.14 |
Sugar Paste (thick) |
|
05.04.07 |
Sulfadiazine |
|
05.01.08 |
Sulfamethoxypyridazine (sulphamethoxypyridazine) |
Dermatology only
Unlicensed
|
01.05.01 |
Sulfasalazine Gastroenterology |
|
10.01.03 |
Sulfasalazine EC Salazopyrin EN-Tabs®) (Rheumatology |
|
04.02.01 |
Sulpiride |
|
04.02.01 |
Sulpiride |
|
04.07.04.01 |
Sumatriptan |
First line oral triptan
|
04.07.04.01 |
Sumatriptan Imigran Subject® |
For migraine if oral or nasal preparations fail, or for cluster headache.
6mg/0.5ml pre-filled syringes in a cartridge pack for use in conjunction with an auto injector for subcutaneous injection.
Note: sumatriptan injection as pre-filled pens (Sun Pharmaceuticals) are non-formulary (see below). |
04.07.04.01 |
Sumatriptan Imigran® |
|
08.01.05 |
Sunitinib |
|
13.08.01 |
Sunsense ® Ultra SPF 50+ |
Borderline substance (ACBS). |
09.03 |
Susoctocog alfa Obizur® |
In line with clinical commissioning policy
|
15.01.05 |
Suxamethonium Chloride |
|
13.05.02 |
Tacalcitol Curatoderm® |
|
08.02.02 |
Tacrolimus |
Red for renal transplant
Amber for all other indications
Specify brand
Second line for resistant nephrotic syndrome
MR cap for continuation in established patients only |
08.02.02 |
Tacrolimus |
Only for patients already receiving tacrolimus who become nil by mouth |
13.05.03 |
Tacrolimus |
0.03% and 0.1% |
13.14 |
Tacrolimus |
0.1% and 0.3%
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
|
07.04.05 |
Tadalafil |
For use if sildenafil not tolerated/effective, or longer duration of action required. Prescribe as generic, on-demand.
Once-daily use and regular use post-prostatectomy not supported (DPC Aug 2014 and Apr 2018). |
02.14 |
Tafamidis Vyndaqel |
Specialist use only. NHS England specialised commissioning for treatment of transthyretin amyloid cardiomyopathy in adults in Trusts providing specialised amyloidosis services.
Available via MHRA EAMS application for eligible patients.
Not routinely stocked at UHS. If required, liaise with lead divisional pharmacist.
|
11.06 |
Tafluprost |
Not a first line choice.
Preservative-free.
Only for patients allergic/intolerant of preservatives, or high risk for developing allergy.
|
11.06 |
Tafluprost with timolol Taptiqom® |
Not a first line choice.
Preservative-free.
Only for patients allergic/intolerant of preservatives, or high risk of developing allergy
|
08.01.05 |
Talimogene laherparepvec Imlygic® |
Observe special precautions for handling and disposal (refer to SPC section 6.6) |
08.03.04.01 |
Tamoxifen |
Liquid restricted for patients unable to swallow tablets
|
07.04.01 |
Tamsulosin |
|
07.04.01 |
Tamsulosin and Solifenacin Vesomni® |
For men not adequately responding to monotherapy |
04.07.02 |
Tapentadol |
Specialist recommendation for third or fourth line use
Liquid for breakthrough pain for patients taking MR tablets only |
05.01 |
Taurolidine Taurolock® |
For use as a line lock in patients on long-term TPN or IV fluids |
05.01 |
Taurolidine, citrate and heparin TauroLock-Hep500® |
For use as a line lock in patients on long-term TPN or IV fluids |
05.01.07 |
Teicoplanin |
|
04.01.01 |
Temazepam |
|
05.01.01.02 |
Temocillin |
Specialist use only
|
08.01.05 |
Temozolomide |
|
02.10.02 |
Tenecteplase Metalyse® |
|
05.03.01 |
Tenofovir disoproxil fumarate |
|
A2.01.03.02 |
Tentrini ® |
Not held in stock but available to order through pharmacy
8x 500ml
Paediatric wards only |
A2.01.03.04 |
Tentrini ®energy |
Not held in stock but available to order through pharmacy
8 x 500ml
Paediatric wards only |
A2.01.03.02 |
Tentrini ®Multifibre |
Not held in stock but available to order through pharmacy
8 x 500ml
Paediatric wards only |
A2.01.02.01 |
Tentrini® energy multifibre |
Not held in stock but available to order through pharmacy
8 x 500ml
Paediatric wards only |
05.02.05 |
Terbinafine |
|
13.10.02 |
Terbinafine 1% |
Can be purchased OTC for athlete's foot or Dhobie itch/jock itch.
|
03.01.01.01 |
Terbutaline |
|
07.01.03 |
Terbutaline |
|
08.02.04 |
Teriflunomide |
|
06.06.01 |
Teriparatide |
Specialist use only.
In addition to licensed indications, also used for treatment of atypical subtrochanteric fractures. |
06.05.02 |
Terlipressin |
|
06.01.06 |
Test Strips Keto-Diastix® |
Ketones and glucose |
06.01.06 |
Test Strips Multistix 8SG® |
Glucose, protein, pH, ketones, specific gravity, blood, nitrite, leucocytes |
06.01.06 |
Test Strips Multistix SG® |
Glucose, protein, blood, ketones, urobiligen, pH, bilirubin, specific gravity |
06.01.06 |
Test Strips Uristix® |
Protein and glucose |
06.04.02 |
Testosterone |
unlicensed
for hypoactive sexual desire disorder associated with surgically-induced menopause |
06.04.02 |
Testosterone 2% Tostran® |
for proven hypogonadism with marked clinical symptoms
Multi-dose pump. One press of the canister piston delivers 0.5g of gel containing 10mg testosterone.
|
06.04.02 |
Testosterone 20mg/g Testavan® |
for proven hypogonadism with marked clinical symptoms.
Preferred brand of testosterone gel locally - DPC Feb 2020. |
06.04.02 |
Testosterone 50mg/5g Testogel® |
for proven hypogonadism with marked clinical symptoms |
06.04.02 |
Testosterone enantate |
|
06.04.02 |
Testosterone injection Sustanon® |
GUM only |
06.04.02 |
Testosterone undecanoate Nebido® |
for hypogonadism |
14.05.02 |
Tetanus immunoglobulin |
|
04.09.03 |
Tetrabenazine |
|
11.07 |
Tetracaine (amethocaine) Minims® |
|
15.02 |
Tetracaine (Amethocaine) Ametop® |
|
06.05.01 |
Tetracosactide Synacthen® |
|
03.07 |
Tezacaftor/ivacaftor Symkevi® |
Restricted to patients as per NHS England commissioning policies |
08.02.04 |
Thalidomide |
Also for renal cell carcinoma |
03.01.03 |
Theophylline |
Prescribe by brand
Slo-Phyllin/Nuelin SA preferred brands at UHS, other brands available for existing patients |
09.06.02 |
Thiamine (vitamin B1) |
|
15.01.01 |
Thiopental |
|
08.01.01 |
Thiotepa |
For treatment of CNS diffuse large B cell lymphoma |
04.08.01 |
Tiagabine Gabitril® |
|
06.04.01.01 |
Tibolone |
|
02.09 |
Ticagrelor |
For patients temporarily unable to swallow |
02.09 |
Ticagrelor Brilique® |
|
05.01.01.04 |
Ticarcillin with clavulanic acid |
Specialist use only
|
02.09 |
Ticlopidine |
unlicensed
Specialist use only.
|
05.01.03 |
Tigecycline |
Specialist use only
|
13.05.03 |
Tildrakizumab Ilumetri® |
|
11.06 |
Timolol |
First line beta-blocker.
Unit dose drops/gel only for patients allergic/intolerant of preservative, or high risk of developing allergy
Eysano® preservative free 0.25% or 0.5% eye drops: Consider as a more cost-effective alternative to other unit drop preparations
Timoptol- LA®: for those with compliance issues with twice daily formulations
|
02.08.01 |
Tinzaparin |
Specialist use off label in paediatrics ONLY for prophylaxis or treatment of thromboembolic disorders in long term/Homecare patients with no necessity to remain in hospital (refer to Southampton Children's Hospital guidelines).
Not for use in adults (enoxaparin is LMWH of choice at UHS for adults).
Multidose vials contain 10mg/ml of the preservative benzyl alcohol: may cause toxic and anaphylactoid reactions in infants and children up to 3 years old. Where possible use alternative CIVAS enoxaparin syringes in neonates.
|
08.01.03 |
Tioguanine |
|
03.01.02 |
Tiotropium |
In UHS initiated by respiratory centre only.
Prescribing by brand name recommended
Inhalation powder caps licensed for COPD only, not for asthma. |
03.01.04 |
Tiotropium and olodaterol Spiolto Respimat® |
Prescribing by brand name recommended
|
02.09 |
Tirofiban Aggrastat® |
|
02.11 |
Tisseel® kit |
Specialist use only
|
08.01.05 |
Tivozanib |
|
10.02.02 |
Tizanidine |
|
05.01.04 |
Tobramycin |
Dry powder inhaler specialist use only
|
05.01.04 |
Tobramycin |
Specialist use only
|
10.01.03 |
Tocilizumab RoActemra® |
Also used off-label for toxicities associated with CAR-T cell therapy
Also available as a treatment option through routine commissioning for adult patients hospitalised with COVID-19 (off label use) in accordance with the criteria set out in the NHS England interim clinical commissioning policy document (see link below)
For use in REMAP-CAP trial for critically ill patients with communty acquired pneumonia, including COVID-19. Seek further advice from infection control specialist/pharmacy.
For use in RECOVERY trial (COVID-19) - restricted to paediatrics PIMS TS only. Seek further advice from infection control specialist/pharmacy. |
01.05.03 |
Tofacitinib XELJANZ® |
|
10.01.03 |
Tofacitinib XELJANZ® |
|
06.01.02.01 |
Tolbutamide |
|
04.09.01 |
Tolcapone Tasmar® |
Specialist initiation.
Only when entacapone or opicapone are inappropriate |
07.04.02 |
Tolterodine |
First line for urinary incontinence (refer to local guidelines and NICE CG171)
|
07.04.02 |
Tolterodine |
Only if problems with compliance/tolerance of immediate-release preparation
|
06.05.02 |
Tolvaptan Jinarc® |
Specialist use only
|
04.07.04.02 |
Topiramate migraine prophylaxis |
|
04.08.01 |
Topiramate epilepsy |
|
08.01.05 |
Topotecan |
|
08.01.05 |
Trabectedin |
|
04.07.02 |
Tramadol |
Inj only for patients who are NBM |
04.07.02 |
Tramadol |
Not a first line option
ONCE daily preparations e.g. 'XL' are non-formulary
( e.g Tradorec XL®, Zamadol® 24hr, and Zydol XL®.)
|
08.01.05 |
Trametinib |
|
02.11 |
Tranexamic Acid |
For menorrhagia |
02.11 |
Tranexamic Acid |
|
02.11 |
Tranexamic acid 5% mouthwash |
Unlicensed special for use in post oral surgery bleeding
|
10.03.02 |
Transvasin® |
For use in the respiratory centre only, prior to capillary blood gas sampling
Contains: Tetrahydrofurfuryl salicylate 14%, ethyl nicotinate 2%, hexyl nicotinate 2% |
08.01.05 |
Trastuzumab |
|
08.01.05 |
Trastuzumab emtansine |
|
11.06 |
Travoprost Travatan® |
Not a first-line choice.
Only for patients with allergy to benzalkonium chloride. Prescribe by brand name as other brands may contain benzalkonium chloride.
|
11.06 |
Travoprost with timolol DuoTrav® |
Not a first-line choice.
Only for patients with allergy to benzalkonium chloride. Prescribe by brand name as other brands may contain benzalkonium chloride.
|
04.03.01 |
Trazodone |
For agitation in older people with dementia |
11.08.01 |
Trehalose/sodium hyaluronate Thealoz Duo® |
To be used in line with DPC dry eye guidelines (link below).
|
08.01.01 |
Treosulfan Trecondi® |
Not appraised by NICE for use prior to alloHSCT in patients with non-malignant disease.
Note: Treosulfan (generic) is non-formulary for palliative treatment of epithelial ovarian cancer. |
08.01.05 |
Tretinoin |
|
13.04 |
Tri-Adcortyl® |
Contains triamcinolone, gramicidin, neomycin and nystatin
ENT only
unlicensed
|
10.01.02.02 |
Triamcinolone Acetonide |
Adcortyl or Kenalog depending on volume |
11.04.01 |
Triamcinolone acetonide Intracinol® |
Specialist ophthalmology use only.
Medical device.
Approved for opacification of the vitreous humour in eye surgery and treatment and prevention of macular oedema in inflammatory eye conditions (off-label). |
10.01.02.02 |
Triamcinolone hexacetonide |
For paediatric rheumatology
|
12.01.01 |
Triamcinolone/gramicidin/neomycin/nystatin Tri-Adcortyl® |
unlicensed
ENT use only for short course treatment
|
09.08.01 |
Trientine |
Specialist use only. For treatment of Wilson's disease only in accordance with NHS England Clinical Commissioning Policy.
Not routinely stocked at UHS. If required please liaise with divisional lead pharmacist.
[N.B. Available as trientine dihydrochloride 300mg capsules and trientine tetrahydrochloride (Cuprior) 150mg tablets. NHS England confirm that both formulations will be commissioned] |
04.02.01 |
Trifluoperazine |
|
08.01.03 |
Trifluridine and tipiracil Lonsurf ® |
NICE TA669: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
|
04.09.02 |
Trihexyphenidyl |
|
05.01.08 |
Trimethoprim |
|
05.04.08 |
Trimethoprim |
|
06.07.02 |
Triptorelin acetate Gonapeptyl Depot® |
This strength restricted to Child Health only
|
06.07.02 |
Triptorelin acetate/pamoate |
Red formulary status for fertility treatment (off label use). Specialist prescribing only.
|
08.03.04.02 |
Triptorelin acetate/pamoate |
|
11.05 |
Tropicamide Minims® |
Preservative-free. |
07.04.02 |
Trospium |
May also be used for treatment of hyperhidrosis (off-label use).
|
02.11 |
Turoctocog alfa pegol Esperoct® |
Haematology specialist use only under NHS England specialised commissioning arrangements.
|
06.07.02 |
Ulipristal Esmya® |
Restricted use only - refer to MHRA Drug Safety Update and product licence.
Ulipristal should no longer be prescribed for controlling symptoms of uterine fibroids while waiting for surgical treatment. |
07.03.05 |
Ulipristal acetate EllaOne® |
An option up to 120 hours postunprotected sexual intercourse |
03.01.02 |
Umeclidinium Incruse Ellipta® |
Prescribing by brand name recommended
Licensed for COPD only, not for asthma |
03.01.04 |
Umeclidinium and vilanterol Anoro Ellipta® |
Prescribing by brand name recommended
|
13.02.01 |
Unguentum M® |
Consider Zeroguent as a more cost effective alternative
|
01.07.02 |
Uniroid HC |
|
10.01.03 |
Upadacitinib Rinvoq® |
|
13.02.01 |
Urea 10% |
e.g. Eucerin Intensive® , Udrate® |
13.02.01 |
Urea 25% Dermatonics Once® |
For use in podiatry only |
13.02.01 |
Urea 25% Allpresan® Diabetic |
For use in podiatry only |
02.10.02 |
Urokinase |
For clearing blocked lines/catheters and treatment of empyema (off-label) only |
01.09.01 |
Ursodeoxycholic acid |
|
01.05.03 |
Ustekinumab Stelara®) (Gastroenterology |
|
10.01.03 |
Ustekinumab Stelara®) (rheumatology |
|
13.05.03 |
Ustekinumab Stelara®) (dermatology |
45mg, 90mg injections (130mg not licensed for dermatology indications).
|
13.08.01 |
Uvistat ® SPF 30 |
Borderline substance (ACBS). |
05.03.02.01 |
Valaciclovir |
|
05.03.02.02 |
Valganciclovir |
|
05.01.07 |
Vancomycin |
Injection only to be used orally when capsules are unable to be given |
05.01.07 |
Vancomycin |
|
04.10.02 |
Varenicline Champix® |
As part of a smoking cessation programme. |
14.04 |
Varicella Zoster vaccine (live) Zostavax® |
Specialist prescribed for severe, intractable, recurrent herpes zoster infection |
14.05.02 |
Varicella-Zoster immunoglobulin VZIG |
Microbiology request only |
14.04 |
Varicella-zoster vaccine |
|
06.05.02 |
Vasopressin |
|
15.01.05 |
Vecuronium Norcuron® |
|
01.05.03 |
Vedolizumab Entyvio® |
June 2020: Subcutaneous formulation supported by District Prescribing Committee for use as an alternative to IV infusion in eligible patients who meet NICE TA criteria |
08.01.05 |
Vemurafenib |
|
08.01.05 |
Venetoclax Venclyxto® |
Venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if:
- there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and conditions for managed access agreement are followed.
|
04.03.04 |
Venlafaxine |
A third line antidepressant |
04.03.04 |
Venlafaxine XL 225mg |
A third line antidepressant |
02.03.02 |
Verapamil |
|
02.03.02 |
Verapamil |
|
02.06.02 |
Verapamil |
|
02.06.02 |
Verapamil |
|
11.08.02 |
Verteporfin Visudyne® |
|
04.08.01 |
Vigabatrin Sabril® |
|
08.01.04 |
Vinblastine |
|
08.01.04 |
Vincristine |
|
08.01.04 |
Vinorelbine |
|
A2.01.02.01 |
Vital® 1.5kcal |
Not held in stock but available to order through pharmacy
200ml - Vanilla |
09.06.07 |
Vitamin and mineral supplements Forceval Soluble® |
For adults with poor swallowing, who are nil by mouth or who require medicine administration through an enteral feeding tube |
09.06.07 |
Vitamin and mineral supplements Ketovite® |
|
09.06.07 |
Vitamin and mineral supplements Sanatogen A-Z Complete® |
|
09.06.07 |
Vitamin and mineral supplements Forceval Junior soluble® |
|
09.06.02 |
Vitamin B compound strong |
Restricted use - see RMOC Position Statement for recommendations on prescribing oral vitamin B supplements.
[Note: UHS may prescribe vitamin B compound strong tablets for patients with Wernicke-Korsakoff syndrome - in this case all supplies (total 1 month) will be made by the hospital].
In rare cases when vitamin B complex prescribing is justified, Vitamin B compound strong should be used in preference to vitamin B compound tablets. |
09.06.01 |
Vitamins A and D |
|
09.06.02 |
Vitamins B and C Pabrinex® |
|
11.99.99.99 |
Viteyes 2® Formula |
Restricted use – Secondary care specialist recommendation for patients who have advanced (category 4) AMD in one eye only.
|
03.01.05 |
Volumatic ® |
|
09.01 |
Vonicog alfa Veyvondi® |
Commissioned by NHS England for treatment and prevention of bleeding in adults with von Willebrand disease. NHS England commissioning policy |
05.02.01 |
Voriconazole |
Specialist use only
|
04.03.04 |
Vortioxetine |
Not a first line antidepressant. |
02.08.02 |
Warfarin |
|
09.02.02.01 |
Water for Injection |
|
13.02.01 |
White Soft Paraffin |
|
A2.03.01 |
Wysoy ® (SMA) |
Ordered via main stores |
12.02.02 |
Xylometazoline Otrivine® |
|
01.07.02 |
Xyloproct ® |
Local anaesthetic plus steroid |
14.04 |
Yellow fever vaccine (Live) |
|
05.03.04 |
Zanamivir Dectova® |
For treatment of complicated and potentially life-threatening influenza A or B virus infection in accordance with official guidance |
05.03.04 |
Zanamivir |
In line with NICE TAs or pandemic flu
|
13.02.01 |
ZeroAQS® |
Similar to aqueous cream but does not contain SLS. Suitable for use as leave-on emollient or soap substitute.
|
13.02.01 |
Zerobase® |
Similar to Diprobase cream |
13.02.01 |
Zerocream ® |
Also suitable for use as a soap substitute.
Similar to E45 cream. |
13.02.01 |
Zeroderm® |
Also suitable for use as a soap substitute or bath additive.
Similar to Epaderm ointment. |
13.02.01 |
Zeroguent® |
Similar to Unguentum M cream
|
05.03.01 |
Zidovudine |
|
05.03.01 |
Zidovudine/lamivudine |
|
13.02.02 |
Zinc and Castor Oil |
First line barrier preparation |
13.05 |
Zinc and salicylic acid Lassar's paste, half strength |
From British Association of Dermatologists (BAD) Specials List 2014
Unlicensed
Where other barrier treatments ineffective |
13.05 |
Zinc and salicylic acid BP Lassar's paste |
|
13.05.01 |
Zinc paste and ichthammol Ichthopaste |
|
09.05.04 |
Zinc Sulfate Solvazinc® |
|
09.05.04 |
Zinc Sulfate |
unlicensed
|
06.06.02 |
Zoledronic acid |
Specialist use only |
06.06.02 |
Zoledronic acid |
Specialist use only
Used in cancer care in preference to pamidronate disodium or sodium clodronate.
'Off label' use for post-menopausal women with breast cancer who are assessed by a specialist to be at sufficient risk of breast cancer recurrence. Refer to DPC shared care guidance: Adjuvant Bisphosphonates for Early Breast Cancer Feb 2018 |
04.07.04.01 |
Zolmitriptan Zomig® |
|
04.08.01 |
Zonisamide Zonegran® |
|
04.01.01 |
Zopiclone |
|
04.02.01 |
Zuclopenthixol acetate Clopixol Acuphase® |
|
04.02.02 |
Zuclopenthixol decanoate Clopixol® |
For deep intramuscular injection
|